<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0146">
    <title>125 Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis</title>
    <sect1 id="ch0146s0001">
      <title>125 Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis</title>
      <anchor id="ch0146s0001a0001"/>
      <anchor id="ch0146s0000a0001"/>
      <para id="ch0146s0000p0001" role="chapterAuthor">DEA GARCIA-HERMOSO, ALEXANDRE ALANIO, FANNY LANTERNIER, AND OLIVIER LORTHOLARY</para>
      <para id="ch0146s0000p0002">Mucormycosis and entomophthoromycosis are invasive fungal infections caused by environmental pauciseptate filamentous fungi. Mucormycosis is caused by the ubiquitous<emphasis>Mucorales</emphasis> and occurs mostly in immunocompromised patients or those with diabetes mellitus. These fungi are responsible for rhinocerebral, pulmonary, cutaneous, and disseminated infections characterized by angioinvasion, necrosis, and severe prognosis despite current antifungal and surgical therapies. Entomophthoromycosis, which occurs mostly in apparently immunocompetent hosts, is caused by members of <emphasis>Entomophthorales</emphasis> (responsible for conidiobolomycosis) and <emphasis>Basidiobolales</emphasis> (responsible for basidiobolomycosis), both mostly found in warm climates. Entomophthoromycosis presents as subcutaneous infections with favorable outcome after prolonged azole therapy without surgery, although it is potentially associated with disfiguring lesions.</para>
      <sect2 id="ch0146s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0146s0001a0002"/>
        <anchor id="ch0146s0000a0002"/>
        <para id="ch0146s0000p0003">The classification of the kingdom<emphasis>Fungi</emphasis> has been constantly modified over the last decades. A comprehensive phylogenetic study based on multigene sequence analyses (<link linkend="ch0146s0000li0001">1</link>) stated the creation of the subphylum <emphasis>Dikarya</emphasis>, which included members of <emphasis>Ascomycota</emphasis> and <emphasis>Basidiomycota</emphasis>, and the redistribution of taxa located in the phyla <emphasis>Zygomycota</emphasis> and <emphasis>Chytridiomycota.</emphasis> The etiological agents responsible for mucormycosis (order <emphasis>Mucorales</emphasis>) and those responsible for entomophthoromycosis (orders <emphasis>Entomophthorales</emphasis> and <emphasis>Basidiobolales</emphasis>) were traditionally assigned to the lower fungus phylum <emphasis>Zygomycota.</emphasis> In this study, this phylum was no longer accepted because of its polyphyletic nature (<link linkend="ch0146s0000li0001">1</link>). The core group of <emphasis>Mucorales</emphasis> and the order <emphasis>Entomophthorales</emphasis> were then included in the subphyla <emphasis>Mucoromycotina</emphasis> and <emphasis>Entomophthoromycotina</emphasis>, respectively.</para>
        <para id="ch0146s0000p0004">In 2016, Spatafora and colleagues (<link linkend="ch0146s0000li0002">2</link>) proposed the new phylum <emphasis>Mucoromycota</emphasis>, which includes three subphyla (<emphasis>Mucoromycotina, Mortierellomycotina</emphasis>, and <emphasis>Glomeromycotina</emphasis>). Of note, the latest phylogenetic revision considered the elevation of the subphylum <emphasis>Glomeromycotina</emphasis> to phylum status. Therefore, the division <emphasis>Mucoromycota</emphasis> comprises two subphyla: <emphasis>Mucoromycotina</emphasis> (including the orders <emphasis>Mucorales</emphasis> and <emphasis>Endogonales</emphasis>) and <emphasis>Mortierellomycotina</emphasis> (order <emphasis>Mortierellales</emphasis>) (<link linkend="ch0146s0000li0003">3</link>).</para>
        <para id="ch0146s0000p0005">In recent years, phylogenetic interactions among members of the order<emphasis>Mucorales</emphasis> have been studied (<link linkend="ch0146s0000li0004">4</link>–<link linkend="ch0146s0000li0006">6</link>). These studies have mainly shown the polyphyletic nature of families (<emphasis>Thamnidiaceae, Mucoraceae</emphasis>, and <emphasis>Chaetocladiaceae</emphasis>) and genera such as <emphasis>Absidia</emphasis> and <emphasis>Mucor.</emphasis> The family structure of <emphasis>Mucorales</emphasis> was studied by Hoffmann and colleagues on the basis of the phylogenetic analysis of four markers (<link linkend="ch0146s0000li0007">7</link>). <emphasis>Rhizopodaceae</emphasis> is one of the newly erected families, and it includes the genus <emphasis>Rhizopus</emphasis> and other pathogenic genera.</para>
        <para id="ch0146s0000p0006">Revisions of other genera have been published in recent years and are detailed below (<link linkend="ch0146s0000li0005">5</link>, <link linkend="ch0146s0000li0008">8</link>–<link linkend="ch0146s0000li0012">12</link>). Of note, the first analysis of a genome sequence from a member of the <emphasis>Mucorales</emphasis> (<emphasis>Rhizopus arrhizus</emphasis>) was published in 2009 (<link linkend="ch0146s0000li0013">13</link>). Currently, several genomes for more than 20 species of <emphasis>Mucorales</emphasis> are available (<ulink url="https://www.ncbi.nlm.nih.gov/genome/">https://www.ncbi.nlm.nih.gov/genome/</ulink>).</para>
        <para id="ch0146s0000p0007"><anchor id="ch0146s0000a0003"/><link linkend="ch0146s0000a0004">Table 1</link> displays the <emphasis>Mucorales</emphasis> species that have been described as human pathogens or potential human pathogens, considering the new family structure published by Hoffmann et al. (<link linkend="ch0146s0000li0007">7</link>).</para>
        <para id="ch0146s0000p0008">Recently, the subphylum<emphasis>Entomophthoromycotina</emphasis> was elevated to the phylum <emphasis>Entomophthoromycota.</emphasis> The monophyly of these organisms was then confirmed by multigene phylogeny analysis (<link linkend="ch0146s0000li0014">14</link>, <link linkend="ch0146s0000li0015">15</link>). This newly erected phylum comprises more than 250 species distributed among three classes (<emphasis>Basidiobolomycetes, Neozygitomycetes</emphasis>, and <emphasis>Entomophthoromycetes</emphasis>) and six families (<emphasis>Basidiobolaceae, Neozygitaceae, Ancylistaceae, Completoriaceae, Entomophthoraceae</emphasis>, and <emphasis>Meristracraceae</emphasis>). There are more than 25 species in the genus <emphasis>Conidiobolus</emphasis>, but only three (<emphasis>Conidiobolus coronatus, C. lamprauges</emphasis>, and <emphasis>C. incongruus</emphasis>) have been recovered from clinical specimens; in the genus <emphasis>Basidiobolus, Basidiobolus ranarum</emphasis> is the only species to provoke human disease (<link linkend="ch0146s0000li0016">16</link>, <link linkend="ch0146s0000li0017">17</link>).</para>
        <table id="ch0146s0000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0146s0000a0004"/><link linkend="ch0146s0000a0003">TABLE 1</link></phrase></emphasis> Species of <emphasis>Mucorales</emphasis> (subphylum <emphasis>Mucoromycotina</emphasis>) involved in human mucormycosis
</title>
          
          <tgroup cols="3">
            <tbody>
              <row>
                <entry><para id="ch0146s0000p0009"><phrase role="center">Family</phrase>
                  </para>
                </entry>
                <entry><phrase role="center">Genus</phrase>
                </entry>
                <entry><phrase role="center">Species</phrase>
                </entry>
              </row>
              <row>
                <entry><emphasis>Lichtheimiaceae</emphasis>
                </entry>
                <entry><emphasis>Lichtheimia</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0010"><emphasis>L. corymbifera</emphasis> (syn., <emphasis>Mycocladus corymbifer</emphasis>; <emphasis>Absidia corymbifera</emphasis>)</para>
                  <para id="ch0146s0000p0011"><emphasis>L. ramosa</emphasis> (syn., <emphasis>Absidia ramosa</emphasis>)</para>
                  <para id="ch0146s0000p0012"><emphasis>L. ornata</emphasis> (syn., <emphasis>Absidia ornata</emphasis>)</para>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><emphasis>Rhizomucor</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0013"><emphasis>R. pusillus</emphasis>
                  </para>
                  <para id="ch0146s0000p0014"><emphasis>R. miehei</emphasis>
                  </para>
                </entry>
              </row>
              <row>
                <entry><emphasis>Mucoraceae</emphasis>
                </entry>
                <entry><emphasis>Mucor</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0015"><emphasis>M. circinelloides</emphasis>
                  </para>
                  <para id="ch0146s0000p0016"><emphasis>M. griseocyanus</emphasis>
                  </para>
                  <para id="ch0146s0000p0017"><emphasis>M. janssenii</emphasis>
                  </para>
                  <para id="ch0146s0000p0018"><emphasis>M. variicolumellatus</emphasis>
                  </para>
                  <para id="ch0146s0000p0019"><emphasis>M. lusitanicus</emphasis>
                  </para>
                  <para id="ch0146s0000p0020"><emphasis>M. indicus</emphasis>
                  </para>
                  <para id="ch0146s0000p0021"><emphasis>M. velutinosus</emphasis>
                  </para>
                  <para id="ch0146s0000p0022"><emphasis>M. irregularis</emphasis> (formerly <emphasis>Rhizomucor variabilis</emphasis> var. <emphasis>variabilis</emphasis>)</para>
                  <para id="ch0146s0000p0023"><emphasis>M. ramosissimus</emphasis>
                  </para>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><emphasis>Actinomucor</emphasis>
                </entry>
                <entry><emphasis>Ac. elegans</emphasis>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><emphasis>Cokeromyces</emphasis>
                </entry>
                <entry><emphasis>C. recurvatus</emphasis>
                </entry>
              </row>
              <row>
                <entry><emphasis>Saksenaeaceae</emphasis>
                </entry>
                <entry><emphasis>Saksenaea</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0024"><emphasis>S. vasiformis</emphasis>
                  </para>
                  <para id="ch0146s0000p0025"><emphasis>S. erythrospora</emphasis>
                  </para>
                  <para id="ch0146s0000p0026"><emphasis>S. oblongispora</emphasis>
                  </para>
                  <para id="ch0146s0000p0027"><emphasis>S. trapezispora</emphasis>
                  </para>
                  <para id="ch0146s0000p0028"><emphasis>S. loutrophoriformis</emphasis>
                  </para>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><emphasis>Apophysomyces</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0029"><emphasis>A. elegans</emphasis>
                  </para>
                  <para id="ch0146s0000p0030"><emphasis>A. trapeziformis</emphasis>
                  </para>
                  <para id="ch0146s0000p0031"><emphasis>A. ossiformis</emphasis>
                  </para>
                  <para id="ch0146s0000p0032"><emphasis>A. variabilis</emphasis>
                  </para>
                  <para id="ch0146s0000p0033"><emphasis>A. mexicanus</emphasis>
                  </para>
                </entry>
              </row>
              <row>
                <entry><emphasis>Rhizopodaceae</emphasis>
                </entry>
                <entry><emphasis>Rhizopus</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0034"><emphasis>R. microsporus</emphasis>
                  </para>
                  <para id="ch0146s0000p0035"><emphasis>R. arrhizus</emphasis> (var. <emphasis>arrhizus</emphasis> and var. <emphasis>delemar</emphasis>)</para>
                  <para id="ch0146s0000p0036"><emphasis>R. schipperae</emphasis>
                  </para>
                </entry>
              </row>
              <row>
                <entry><emphasis>Syncephalastraceae</emphasis>
                </entry>
                <entry><emphasis>Syncephalastrum</emphasis>
                </entry>
                <entry><emphasis>S. racemosum</emphasis>
                </entry>
              </row>
              <row>
                <entry><emphasis>Cunninghamellaceae</emphasis>
                </entry>
                <entry><emphasis>Cunninghamella</emphasis>
                </entry>
                <entry><para id="ch0146s0000p0037"><emphasis>C. bertholletiae</emphasis>
                  </para>
                  <para id="ch0146s0000p0038"><emphasis>C. echinulata</emphasis>
                  </para>
                  <para id="ch0146s0000p0039"><emphasis>C. elegans</emphasis>
                  </para>
                  <para id="ch0146s0000p0040"><emphasis>C. blakesleeana</emphasis>
                  </para>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
      </sect2>
      <sect2 id="ch0146s0001s0002">
        <title>MUCORMYCOSIS</title>
        <anchor id="ch0146s0001a0003"/>
        <anchor id="ch0146s0000a0005"/>
        <anchor id="ch0146s0000a0006"/>
      </sect2>
    </sect1>
    <sect1 id="ch0146s0002">
      <title>Epidemiology and Transmission</title>
      <anchor id="ch0146s0002a0001"/>
      <anchor id="ch0146s0000a0007"/>
      <para id="ch0146s0000p0041"><emphasis>Mucorales</emphasis> are ubiquitous fungi widely distributed in the environment (soil, plants, and decaying organic material) (<link linkend="ch0146s0000li0018">18</link>). They are frequent pathogens of plants and contaminants of grains and food such as fruit and bread. Airborne spores are considered the infectious particles responsible for disease, particularly in immunocompromised individuals, explaining the most frequent body localizations (sinuses, lungs, and skin). A comprehensive study of cases diagnosed in France noted that immunocompetent patients may develop posttrauma skin infections, representing up to 18% of all mucormycosis cases (<link linkend="ch0146s0000li0019">19</link>). In addition, necrotizing cutaneous cases were reported after a tornado in Joplin, MO (<link linkend="ch0146s0000li0020">20</link>), and following combat-related injuries in Afghanistan (<link linkend="ch0146s0000li0021">21</link>). These species are easily found as laboratory contaminants and can be a source of nosocomial infections, including outbreaks (<link linkend="ch0146s0000li0022">22</link>–<link linkend="ch0146s0000li0027">27</link>). Overall, <emphasis>Rhizopus arrhizus</emphasis> is the most common species involved in human disease, followed by species of <emphasis>Lichtheimia, Rhizomucor, Rhizopus microsporus, Mucor circinelloides</emphasis>, and <emphasis>Apophysomyces.</emphasis> However, these agents may vary depending on the geographical area. Thus, the second most isolated species are <emphasis>Lichtheimia corymbifera</emphasis> and <emphasis>Apophysomyces</emphasis> spp. in Europe (<link linkend="ch0146s0000li0013">13</link>, <link linkend="ch0146s0000li0028">28</link>, <link linkend="ch0146s0000li0029">29</link>) and in India (<link linkend="ch0146s0000li0030">30</link>), respectively.</para>
      <para id="ch0146s0000p0042">Some reports have suggested an increasing incidence of mucormycosis, based on single-center studies (<link linkend="ch0146s0000li0031">31</link>–<link linkend="ch0146s0000li0035">35</link>). In a retrospective analysis of hospital records in France, our group provided a population-based estimate of mucormycosis incidence and trends for the country over a 10-year period (<link linkend="ch0146s0000li0036">36</link>). Using two available sources of information, we then better estimated the real burden of mucormycosis infections through a capture-recapture method (<link linkend="ch0146s0000li0037">37</link>) and found different incidences according to region, suggesting local ecological specificities at a country level (<link linkend="ch0146s0000li0038">38</link>). The incidence significantly increased over time, with an average annual incidence rate of 0.9/10<superscript>6</superscript> population, which is different from the incidences reported in a population-based study in California in 1992 to 1993 (1.7/10<superscript>6</superscript>) (<link linkend="ch0146s0000li0039">39</link>) and in Spain in 2005 (0.43/10<superscript>6</superscript>) (<link linkend="ch0146s0000li0040">40</link>). Such an increasing trend was further confirmed in France (<link linkend="ch0146s0000li0041">41</link>). The sex ratio (M/F) (1.8 versus 1.1) and mean age (38.8 versus 57.1 years) differ in the review of 929 cases published between 1940 and 1999 and in France (<link linkend="ch0146s0000li0036">36</link>, <link linkend="ch0146s0000li0042">42</link>). Of note, a nonsignificant trend in terms of incidence over time was found among the 314 cases of mucormycosis recorded during the 7-year analysis of 10,886 episodes of invasive fungal diseases in France (<link linkend="ch0146s0000li0029">29</link>).</para>
      <anchor id="ch0146s0000a0008"/>
      <beginpage pagenum="2445"/>
      <para id="ch0146s0000p0043">Diabetes is a major risk factor (23% in France and up to 36% of the cases elsewhere, 20% with type 1 diabetes) (<link linkend="ch0146s0000li0019">19</link>, <link linkend="ch0146s0000li0042">42</link>, <link linkend="ch0146s0000li0043">43</link>), with a significant increase in the incidence of diabetes-associated mucormycosis recently documented in France (<link linkend="ch0146s0000li0036">36</link>) and in a tertiary-care center in North India (<link linkend="ch0146s0000li0044">44</link>). In the latter study, 131 of 178 cases were observed in patients with uncontrolled diabetes (73.6%), and more importantly, mucormycosis led to the diagnosis of diabetes in 56 cases (42.7% of diabetes cases). Diabetes mellitus was also found in 15% (type 1 = 13%) of 157 pediatric cases (<link linkend="ch0146s0000li0045">45</link>). Diabetes was an independent risk factor for mucormycosis in patients with leukemia and/or bone marrow transplantation (<link linkend="ch0146s0000li0032">32</link>) and significantly influenced the occurrence of mucormycosis during solid organ transplantation (SOT) (<link linkend="ch0146s0000li0019">19</link>, <link linkend="ch0146s0000li0046">46</link>). Recently, diabetes has also been recognized as a risk factor and prognostic indicator for mucormycosis occurring in patients with severe coronavirus disease 2019 (COVID-19) in both India and France (<link linkend="ch0146s0000li0047">47</link>–<link linkend="ch0146s0000li0051">51</link>). Of note, the most frequent clinical presentation of diabetes-associated mucormycosis is sinusitis. Among patients with hematological malignancies, which represented 50% of the cases in France (<link linkend="ch0146s0000li0019">19</link>), those with acute leukemia (profound neutropenia or relapse) or allogeneic stem cell transplantation are more prone to develop mucormycosis, the lungs being the site most frequently involved. Mucormycosis most often occurs more than 3 months after transplant in the setting of graft-versus-host disease (<link linkend="ch0146s0000li0032">32</link>, <link linkend="ch0146s0000li0033">33</link>, <link linkend="ch0146s0000li0035">35</link>, <link linkend="ch0146s0000li0052">52</link>–<link linkend="ch0146s0000li0056">56</link>). Mucormycosis now represents 7% to 8% of invasive fungal infections in bone marrow transplant patients (<link linkend="ch0146s0000li0057">57</link>, <link linkend="ch0146s0000li0058">58</link>). An increased incidence of mucormycosis was observed in patients with hematological malignancies or stem cell transplant in France (<link linkend="ch0146s0000li0036">36</link>), as already noted in the 1990s in one U.S. center (<link linkend="ch0146s0000li0035">35</link>). In that population, the potential role of prior exposure to antifungals such as voriconazole and caspofungin that lack activity against <emphasis>Mucorales</emphasis> was reported (<link linkend="ch0146s0000li0032">32</link>, <link linkend="ch0146s0000li0033">33</link>, <link linkend="ch0146s0000li0046">46</link>, <link linkend="ch0146s0000li0059">59</link>–<link linkend="ch0146s0000li0062">62</link>). More recently, mucormycosis cases have been identified in patients with chronic lymphoid malignancies receiving recently introduced agents such as ibrutinib (<link linkend="ch0146s0000li0063">63</link>, <link linkend="ch0146s0000li0064">64</link>).</para>
      <para id="ch0146s0000p0044">Mucormycosis represents 2% of invasive fungal infections during SOT, mostly in kidney transplantation (<link linkend="ch0146s0000li0065">65</link>). In an international prospective study of SOT recipients, renal failure, diabetes mellitus, and prior voriconazole and/or caspofungin use were associated with a higher risk of mucormycoses, whereas tacrolimus was associated with a lower risk (<link linkend="ch0146s0000li0046">46</link>). Liver transplant recipients were more likely to have disseminated disease and developed infection significantly earlier after transplantation than other SOT recipients.</para>
      <para id="ch0146s0000p0045">Mucormycosis can also develop in HIV-infected patients and in intravenous-drug users. It can affect otherwise healthy individuals after cutaneous injuries with contaminated soil, in almost 20% of the cases in some studies. Finally, it may present as community-acquired or as a health care-related disease. A careful review of cases published between 1970 and 2008 revealed 169 mucormycosis cases associated with health care (with 29% of them in children), of which 72% were published after 1990 (<link linkend="ch0146s0000li0023">23</link>). Mucormycosis has also been described in the context of contaminated graft during travel-associated transplantation (<link linkend="ch0146s0000li0066">66</link>). Outbreaks of mucormycosis are rare but have been related to building construction and use of contaminated adhesive tape, ostomy bags, and wooden tongue depressors and more recently to contaminated linens, notably in pediatric hospitals (<link linkend="ch0146s0000li0026">26</link>, <link linkend="ch0146s0000li0067">67</link>, <link linkend="ch0146s0000li0068">68</link>).</para>
    </sect1>
    <sect1 id="ch0146s0003">
      <title>Clinical Manifestations</title>
      <anchor id="ch0146s0003a0001"/>
      <anchor id="ch0146s0000a0009"/>
      <para id="ch0146s0000p0046">Localized and disseminated diseases need to be differentiated (<link linkend="ch0146s0000li0054">54</link>). The most frequent localized forms are sinusitis and pneumonia, representing 25% to 39% and 24% to 30% of clinical sites involved, respectively, in three recent series (<link linkend="ch0146s0000li0019">19</link>, <link linkend="ch0146s0000li0028">28</link>, <link linkend="ch0146s0000li0042">42</link>). Dissemination rates vary from 3% to more than 50% in patients with hematological malignancies (depending to some extent on the underlying diseases and the site of infection) (<link linkend="ch0146s0000li0042">42</link>, <link linkend="ch0146s0000li0054">54</link>, <link linkend="ch0146s0000li0055">55</link>).</para>
      <para id="ch0146s0000p0047">Sinus involvement (isolated sinusitis, rhinocerebral, and sinoorbital forms) is the most common presentation in diabetes patients and intravenous-drug users, and pulmonary infection is the second most common presentation; the reverse is true in hematology patients (<link linkend="ch0146s0000li0032">32</link>, <link linkend="ch0146s0000li0042">42</link>). Infection causes necrosis and hemorrhage and may be localized or associated with dissemination. Clinicoradiological presentation is similar to that of invasive aspergillosis in patients with hematological malignancies, although the presence of a reversed halo sign may be suggestive of (<link linkend="ch0146s0000li0069">69</link>, <link linkend="ch0146s0000li0070">70</link>) but not specific to (<link linkend="ch0146s0000li0071">71</link>, <link linkend="ch0146s0000li0072">72</link>) mucormycosis. This radiological sign is transient. In a recent study of 58 SOT patients with mucormycosis, pulmonary localization was present in 31 (53%), including 23 with localized infection (<link linkend="ch0146s0000li0073">73</link>).</para>
      <para id="ch0146s0000p0048">Localized cutaneous lesions are most often encountered in immunocompetent hosts (<link linkend="ch0146s0000li0042">42</link>) and follow injury and contamination with airborne spores or soil (<link linkend="ch0146s0000li0074">74</link>–<link linkend="ch0146s0000li0076">76</link>) and, less often, surgery or burns (<link linkend="ch0146s0000li0025">25</link>). Local extension and hematogenous dissemination may occur. In contrast, skin lesions resulting from dissemination from other sites are rare.</para>
      <para id="ch0146s0000p0049">Cerebral infection can complicate sinusitis or can occur independently, especially in intravenous-drug users. Cognitive disturbances and focal neurological deficits are often present. Gastrointestinal lesions are described in 7% of cases and occur in low-birthweight, premature infants and malnourished individuals and after peritoneal dialysis (<link linkend="ch0146s0000li0042">42</link>). They are responsible for abdominal pain and digestive hemorrhage, and complications include digestive tract perforation, peritonitis, and dissemination to the liver.</para>
    </sect1>
    <sect1 id="ch0146s0004">
      <title>Treatment</title>
      <anchor id="ch0146s0004a0001"/>
      <anchor id="ch0146s0000a0010"/>
    </sect1>
    <sect1 id="ch0146s0005">
      <title>■ Prophylaxis</title>
      <anchor id="ch0146s0005a0001"/>
      <anchor id="ch0146s0000a0011"/>
      <para id="ch0146s0000p0050">In immunocompromised patients, there is no benefit to the prophylactic use of azoles such as fluconazole, itraconazole, and voriconazole because of the lack of (major) activity against<emphasis>Mucorales</emphasis> (<link linkend="ch0146s0000li0035">35</link>, <link linkend="ch0146s0000li0055">55</link>, <link linkend="ch0146s0000li0056">56</link>). The best preventive measure is the reduction of environmental exposure, notably with the use of high-efficiency particulate air filters for rooms (<link linkend="ch0146s0000li0055">55</link>). The specific role of posaconazole as a prophylactic agent against mucormycosis has not been demonstrated (<link linkend="ch0146s0000li0077">77</link>, <link linkend="ch0146s0000li0078">78</link>), and there has been no decrease in the incidence of the disease in the hematology population over recent years, although posaconazole has been available since 2007 (<link linkend="ch0146s0000li0038">38</link>). In addition, no study has yet investigated isavuconazole as prophylaxis for mucormycosis. Posaconazole and isavuconazole breakthrough infections have been reported (<link linkend="ch0146s0000li0079">79</link>).</para>
    </sect1>
    <sect1 id="ch0146s0006">
      <title>■ Curative Treatment</title>
      <anchor id="ch0146s0006a0001"/>
      <anchor id="ch0146s0000a0012"/>
      <para id="ch0146s0000p0051">Combined medical and radical surgical treatments, especially for rhinocerebral and skin localizations, in association with correction of the underlying disease wherever possible (i.e., acidosis, hyperglycemia, neutrophil recovery, and modulation of immunosuppressive therapy), offer the best chance of survival (<link linkend="ch0146s0000li0080">80</link>–<link linkend="ch0146s0000li0082">82</link>).</para>
      <para id="ch0146s0000p0052">High-dose liposomal amphotericin B (L-AmB) given early in the course of the disease is probably the treatment cornerstone (<link linkend="ch0146s0000li0083">83</link>). Clinical response has been obtained with a high dose of L-AmB in patients who failed with conventional dosages (<link linkend="ch0146s0000li0084">84</link>, <link linkend="ch0146s0000li0085">85</link>), and a clinical trial reported a good response rate with 10 mg/kg of body weight, but with consequent renal toxicity. Therefore, recent guidelines recommend L-AmB as first-line treatment at 5 mg/kg/day and at 7.5 to 10 mg/kg/day when the central nervous system (CNS) is involved (<link linkend="ch0146s0000li0086">86</link>).</para>
      <anchor id="ch0146s0000a0013"/>
      <beginpage pagenum="2446"/>
      <para id="ch0146s0000p0053">Isavuconazole efficacy has been documented in a limited number of patients as first-line therapy, with a 10% response rate at week 12 in the VITAL study (<link linkend="ch0146s0000li0087">87</link>) versus 48% with liposomal amphotericin B in the AmBizygo trial (<link linkend="ch0146s0000li0088">88</link>). Posaconazole in its oral tablet or intravenous formulation can be considered only a second-line therapy; iron chelators such as deferasirox should not be used, and echinocandins in combination with polyenes are considered a second-line therapy option. Global case fatality rates vary from 47% to 84% (<link linkend="ch0146s0000li0042">42</link>), with those of rhinocerebral forms ranging from 20% to 69% (<link linkend="ch0146s0000li0034">34</link>, <link linkend="ch0146s0000li0044">44</link>). Survival is reduced in cases of hematological malignancies compared with diabetes mellitus (<link linkend="ch0146s0000li0019">19</link>).</para>
    </sect1>
    <sect1 id="ch0146s0007">
      <title>Collection, Transport, and Storage of Specimens</title>
      <anchor id="ch0146s0007a0001"/>
      <anchor id="ch0146s0000a0014"/>
      <para id="ch0146s0000p0054">Mucormycosis is one of the most rapidly progressing invasive fungal infections. The diagnosis of mucormycosis should be considered an emergency, because delaying therapy will affect outcome (<link linkend="ch0146s0000li0089">89</link>). Although clinical features are not specific, some early radiological features make the diagnosis of mucormycosis more probable than other invasive fungal infections, particularly invasive aspergillosis (<link linkend="ch0146s0000li0072">72</link>). A combination of well-known predisposing factors and clinical and/or radiological signs must alert the physician and prompt the institution to carry out immediate diagnostic procedures. Since currently available methods developed for the diagnosis of invasive fungal infections are based on antigens that are not produced by <emphasis>Mucorales</emphasis> (<link linkend="ch0146s0000li0090">90</link>), the diagnosis relies mainly on direct examination and/or recovery of the fungus and/or detection of its nucleic acids in pathological tissues, body fluids, or exudates. Blood cultures are not appropriate for diagnosis. In high-risk patients, specimens, preferentially from deep lesions and sterile sites, must be rapidly and aseptically collected in sufficient quantities. Larger volumes will increase the likelihood of fungal recovery and will allow more diagnostic procedures (direct examination, culture, DNA extraction for PCR, and histopathology) as well as storage of the sample for further analyses. For rhinocerebral localization, nasal discharge or scraping, sinus aspirate, or a tissue specimen from an abnormally vascularized area should be obtained. For pulmonary localization, sputum, bronchial aspirate, and bronchoalveolar lavage (BAL) fluids can be examined, considering the low sensitivity of these specimens (<link linkend="ch0146s0000li0091">91</link>, <link linkend="ch0146s0000li0092">92</link>). Transbronchial or percutaneous computerized tomography-guided biopsies of pulmonary lesions can be performed, but the potential for induced morbidity must be kept in mind (<link linkend="ch0146s0000li0093">93</link>).</para>
      <para id="ch0146s0000p0055">Separate specimens must be sent for microbiological and histological analysis, because formalin, which is used for histopathology, inhibits fungal growth. Direct examination remains the most rapid diagnostic technique, and culture is still an essential step to test susceptibility to antifungal drugs. Reliable identification at the species level still relies on obtaining the isolate in culture. The transport container should be sterile and humidified with a few drops of sterile saline. The specimen should not be refrigerated and should ideally be transported to the laboratory within 2 h after collection and processed rapidly, because<emphasis>Mucorales</emphasis> are easily damaged and sensitive to environmental stresses (<link linkend="ch0146s0000li0094">94</link>). Biopsy specimen grinding is deleterious to the <emphasis>Mucorales</emphasis> because of the coenocytic nature of the hyphae. Biopsy specimens should be sliced into small pieces of tissue that are then dispatched for direct examination and culture.</para>
    </sect1>
    <sect1 id="ch0146s0008">
      <title>Direct Examination and Histopathology</title>
      <anchor id="ch0146s0008a0001"/>
      <anchor id="ch0146s0000a0015"/>
      <para id="ch0146s0000p0056">Demonstration of hyphae in clinical samples provides strong evidence of mucormycosis because<emphasis>Mucorales</emphasis> are environmental airborne moulds that could be present in conidial form in nonsterile specimens, with false-positive cultures as a result. Direct examination is a key test for two reasons: (i) culture from clinical samples is frequently negative (<link linkend="ch0146s0000li0095">95</link>), and (ii) histology requires multiple steps that necessarily delay diagnosis.</para>
    </sect1>
    <sect1 id="ch0146s0009">
      <title>■ Microscopy</title>
      <anchor id="ch0146s0009a0001"/>
      <anchor id="ch0146s0000a0016"/>
      <para id="ch0146s0000p0057">Direct examination can be performed with wet mounts of the sample or after addition of chlorazol black. However, an optical brightener (calcofluor white, Blankophor, or Uvitex 2B) that specifically stains the chitin contained in the cell wall, coupled with a clearing and dissociating agent, such as KOH, provides better sensitivity (<link linkend="ch0146s0000li0091">91</link>). It is always a good idea to examine the slides again the following day, especially in the presence of thick samples, because of possible false negatives resulting from insufficient dissociation of tissues.</para>
      <para id="ch0146s0000p0058">The morphological characteristics suggestive of<emphasis>Mucorales</emphasis> hyphae are specific and can be differentiated from those of <emphasis>Aspergillus, Fusarium</emphasis>, or <emphasis>Scedosporium.</emphasis> Hyphae are large (5 to 25 μm), irregular, hyaline, non- or pauciseptate, and thin walled with a ribbon-like morphology. A twisted or folded appearance of the hyphae is frequently observed. In contrast to the acute (45°) branching pattern observed in hyalohyphomycetes, wide-branching angles (≥90°) are suggestive of <emphasis>Mucorales.</emphasis> If hyphae are fragmented, the typical features are missing, which makes it difficult to make a reliable diagnosis based solely on direct microscopy. However, the same characteristic features can be observed in tissue samples after histopathological preparation based on Gomori methenamine-silver or periodic acid-Schiff staining. Of note, the detection of <emphasis>Mucorales</emphasis> is difficult with use of hematoxylin-eosin stain. Sometimes, if only a few hyphae are present and the tissue section contains cross-sections through the hyphae, it can produce the appearance of yeast or vacuole-like structures, making the morphology difficult to interpret. Classically, <emphasis>Mucorales</emphasis> are angioinvasive, with invasion of venous and arterial walls frequently associated with infarction of the surrounding tissue. The inflammatory response is varied, ranging from none to a neutrophil infiltrate alone, granulomatous response alone, or both together. Perineural invasion can also be observed (<link linkend="ch0146s0000li0096">96</link>). Immunohistochemistry techniques based on commercially available kits can be used in difficult cases (<link linkend="ch0146s0000li0097">97</link>).</para>
    </sect1>
    <sect1 id="ch0146s0010">
      <title>Antigen Detection</title>
      <anchor id="ch0146s0010a0001"/>
      <anchor id="ch0146s0000a0017"/>
      <para id="ch0146s0000p0059">There are currently no commercial specific antigen detection methods available for the diagnosis of mucormycosis. Moreover, β-<emphasis role="smallcaps">D</emphasis>-glucan testing does not perform well in the serum of patients with mucormycosis. However, two promising biomarkers are under development and have been evaluated. The detection of a panfungal disaccharide which was identified as trehalose using mass spectrometry was tested in the serum of patients with invasive fungal infections. Detection of trehalose was possible in 9/16 patients, suggesting that this panfungal marker is potentially interesting for the noninvasive diagnosis of mucormycosis (<link linkend="ch0146s0000li0098">98</link>). In parallel, a monoclonal antibody recognizing alpha-1,6 mannan has been developed based on purified mannans of <emphasis>Mucor, Rhizopus, Aspergillus, Fusarium</emphasis>, and <emphasis>Candida</emphasis> species for use in a lateral-flow assay. This assay should be further tested in the sera of patients with invasive mycoses but constitutes a potential broad biomarker of invasive fungal infection including mucormycosis (<link linkend="ch0146s0000li0099">99</link>).</para>
      <anchor id="ch0146s0000a0018"/>
      <beginpage pagenum="2447"/>
    </sect1>
    <sect1 id="ch0146s0011">
      <title>Isolation Procedures</title>
      <anchor id="ch0146s0011a0001"/>
      <anchor id="ch0146s0000a0019"/>
      <para id="ch0146s0000p0060">Recovery of<emphasis>Mucorales</emphasis> from clinical specimens is difficult, with culture being positive in only 15 to 25% of cases (<link linkend="ch0146s0000li0095">95</link>). However, culture is suitable for the definite diagnosis of mucormycosis, especially in cases of negative direct examination, keeping in mind that the lack of galactomannan antigen detection may indirectly suggest the diagnosis of mucormycosis. Indeed, clinical and radiological features are not specific for invasive fungal infection, nor can they distinguish between mucormycosis and invasive fungal infections due to <emphasis>Aspergillus, Fusarium</emphasis>, or <emphasis>Scedosporium</emphasis>, especially in the hematological setting. However, the therapeutic management is different, and isolation of a fungus is sometimes the unique diagnostic element. Culture is also of prime importance for identification to the species level, especially since morphological structures are not species specific in tissues, and for antifungal susceptibility testing of the isolate (<link linkend="ch0146s0000li0100">100</link>). Primarily, culture is typically performed on rich medium such as Sabouraud dextrose agar, with additional antibiotic to inhibit bacterial growth. Cycloheximide-containing media should not be used, because inhibition of fungal growth can be observed for some species. After inoculation, plates must be incubated between 25 to 30°C and 37°C to allow growth of thermotolerant and thermointolerant isolates (<link linkend="ch0146s0000li0101">101</link>). However, Sabouraud dextrose agar is often not appropriate for morphological identification purposes, and growth on potato dextrose agar (PDA) is more suitable.</para>
    </sect1>
    <sect1 id="ch0146s0012">
      <title>Detection of Nucleic Acids in Clinical Materials</title>
      <anchor id="ch0146s0012a0001"/>
      <anchor id="ch0146s0000a0020"/>
      <para id="ch0146s0000p0061">In many cases, histopathology and/or direct examination is positive, but culture fails. Species identification is, however, important for epidemiological purposes and for species-specific antifungal susceptibility profiles. PCR-based molecular identification can be performed with formalin-fixed, paraffin-embedded (<link linkend="ch0146s0000li0102">102</link>) frozen or fresh tissue specimens. In formalin-fixed, paraffin-embedded tissues, extracted DNA is often of poor quality because of fragmentation after fixation (<link linkend="ch0146s0000li0103">103</link>). Furthermore, extracted DNA usually contains small amounts of fungal DNA relative to the large quantity of human DNA. Consequently, PCR-based identification must rely on amplification of small fragments of DNA that should ideally allow sequence discrimination between species upon sequencing. PCR based on internal transcribed spacer 1 (ITS1) and ITS2 primers followed by sequencing has been proposed in formalin-fixed, paraffin-embedded organs recovered from mice with experimental mucormycosis (<link linkend="ch0146s0000li0104">104</link>). It has also been evaluated in formalin-fixed, paraffin-embedded human tissues, with identification of <emphasis>Mucorales</emphasis> in 7/18 samples harboring nonseptate hyphae, based on histopathological reporting (<link linkend="ch0146s0000li0102">102</link>). A seminested PCR technique based on the 18S ribosomal DNA loci has also been used with <emphasis>Mucorales</emphasis> identification in 13/23 samples for which nonseptate hyphae were observed by histology (<link linkend="ch0146s0000li0105">105</link>). This molecular tool has also been prospectively evaluated with identification of <emphasis>Mucorales</emphasis> in six samples, of which five were culture positive (<link linkend="ch0146s0000li0106">106</link>, <link linkend="ch0146s0000li0107">107</link>). An approach based on real-time PCR has been developed based on cytochrome <emphasis>b</emphasis> locus amplification. It allowed discrimination between different genera of <emphasis>Mucorales</emphasis> using analysis of melting curves (identification of 35/62 formalin-fixed, paraffin-embedded tissue samples) (<link linkend="ch0146s0000li0108">108</link>). Quantitative PCR using multiple target-specific assays has been developed to detect and identify <emphasis>Mucorales</emphasis> in formalin-fixed, paraffin-embedded human tissues (<link linkend="ch0146s0000li0109">109</link>). Multiplex PCR coupled with electrospray ionization in direct-detection-positive, culture-negative unfixed clinical samples seems potentially interesting, allowing genus and species identification (<link linkend="ch0146s0000li0110">110</link>).</para>
      <para id="ch0146s0000p0062">Fluorescent-dye-labeled oligonucleotides with direct hybridization (fluorescent<emphasis>in situ</emphasis> hybridization) on the pathologic tissue is a promising tool because it does not require DNA extractions or PCR amplification and can be performed on formalin-fixed, paraffin-embedded tissue samples. It uses fluorescent DNA probes that are specific for 5.8S or 18S RNA of different groups of fungi. After hybridization, fluorescence of the microorganism can be observed directly on the slide (<link linkend="ch0146s0000li0111">111</link>, <link linkend="ch0146s0000li0112">112</link>). Localization of the fluorescence can provide additional information that can reinforce the diagnosis. This tool seems particularly well adapted for situations in which the yield of DNA extraction or the quality of the extracted DNA is poor. Indeed, PCR-negative, fluorescence <emphasis>in situ</emphasis> hybridization-positive results have been observed (<link linkend="ch0146s0000li0112">112</link>).</para>
    </sect1>
    <sect1 id="ch0146s0013">
      <title>PCR-Based Diagnosis in Serum: Mucormycosis Screening</title>
      <anchor id="ch0146s0013a0001"/>
      <anchor id="ch0146s0000a0021"/>
      <para id="ch0146s0000p0063">In addition to the molecular methods developed for fungal identification from tissues, another strategy, inspired by the screening strategy for patients at risk for aspergillosis, is emerging for the diagnosis of mucormycosis. In a population with a relatively high prevalence of mucormycosis, one recent study proposed to screen sequential serum samples by PCR targeting<emphasis>Mucorales</emphasis> genes of <emphasis>Rhizopus</emphasis> spp., <emphasis>Mucor</emphasis> spp., <emphasis>Rhizomucor</emphasis> spp., and <emphasis>Lichtheimia</emphasis> spp. Using this method, the authors were able to establish the diagnosis of mucormycosis between 3 and 68 days before a diagnosis based on histopathology or culture (<link linkend="ch0146s0000li0113">113</link>).</para>
      <para id="ch0146s0000p0064">A retrospective analysis of 44 patients in a multicentric French study validated these findings. In addition, it showed that a negativation of the quantitative PCR (qPCR) test was associated with a better prognosis than persistently positive qPCR during treatment (<link linkend="ch0146s0000li0114">114</link>). Based on the same qPCR assays, a screening strategy was tested on burn patients with high risk of invasive wound mucormycosis (IWM). After retrospective analysis of patients with and without IWM, PCR was done twice a week, and patients were treated once the PCR became positive. The treatment was stopped after two negative PCR results. This strategy decreased the burden of IWM in this high-risk population and improved outcome (<link linkend="ch0146s0000li0025">25</link>). In addition, a recent prospective study on the performance of this qPCR assay to diagnose mucormycosis provided a sensitivity of 85.2% and specificity of 89.8% for qPCRs that were positive within a median of 4 days before the first positive mycological criteria (<link linkend="ch0146s0000li0067">67</link>). A negative qPCR test 7 days after the beginning of antifungal drug (L-AmB) was associated with a better outcome. This study validated the use of this <emphasis>Mucorales</emphasis> qPCR tool to diagnose and manage patients with mucormycoses (<link linkend="ch0146s0000li0115">115</link>).</para>
      <para id="ch0146s0000p0065">Other PCR assays have been proposed recently with different designs, allowing detection of a broader spectrum of<emphasis>Mucorales</emphasis> with a combination of two assays performed with serum, tissue (<link linkend="ch0146s0000li0116">116</link>, <link linkend="ch0146s0000li0117">117</link>), or BAL fluid (<link linkend="ch0146s0000li0118">118</link>). A commercial assay has been also evaluated with a sensitivity around 75% with the same benefit as the other qPCR assays by detecting circulating DNA with a median of 8 days before classical mycology (<link linkend="ch0146s0000li0119">119</link>). Detection in bronchoalveolar lavage fluids is also possible but needs to be further validated (<link linkend="ch0146s0000li0120">120</link>).</para>
      <anchor id="ch0146s0000a0022"/>
      <beginpage pagenum="2448"/>
      <para id="ch0146s0000p0066">All qPCR assays must be standardized and then could be proposed, as a standard, to diagnose early invasive mucormycosis and could potentially be used in a screening strategy in high-risk patients.</para>
    </sect1>
    <sect1 id="ch0146s0014">
      <title>Identification</title>
      <anchor id="ch0146s0014a0001"/>
      <anchor id="ch0146s0000a0023"/>
    </sect1>
    <sect1 id="ch0146s0015">
      <title>■ Phenotypic Identification</title>
      <anchor id="ch0146s0015a0001"/>
      <anchor id="ch0146s0000a0024"/>
      <sect2 id="ch0146s0015s0001">
        <title>General Description</title>
        <anchor id="ch0146s0015a0002"/>
        <anchor id="ch0146s0000a0025"/>
        <para id="ch0146s0000p0067">Routine identification of<emphasis>Mucorales</emphasis> to the species level is mainly based on the examination of their macroscopic and asexual microscopic characteristics, although some other criteria, such as physiological tests (<link linkend="ch0146s0000li0121">121</link>) and maximum growth temperature, can be used. The formation of zygospores is not useful in routine identification unless the species is homozygous. The use of media with high carbohydrate content favors production of an abundant mycelium, which inhibits the production of asexual fruiting bodies by which the species can be identified. Therefore, media such as 2% malt, potato dextrose, and cherry decoction (acidic) agars are recommended for subculture of most of the <emphasis>Mucorales</emphasis> species, although some of these media are not commercially available. To trigger sporulation in genera such as <emphasis>Apophysomyces</emphasis> or <emphasis>Saksenaea</emphasis>, which are emerging pathogens (<link linkend="ch0146s0000li0122">122</link>–<link linkend="ch0146s0000li0124">124</link>), nutritionally deficient media containing a low percentage of yeast extract solution are advisable (<link linkend="ch0146s0000li0125">125</link>). Multiple factors, such as light and temperature, also influence the growth, the morphology, and the sporulation of these fungi. Several species are thermotolerant, capable of growing at a temperature well over 40°C.</para>
        <para id="ch0146s0000p0068">Mycelial development of the<emphasis>Mucorales</emphasis> tends to be rapid (24 to 48 h) and extensive. Colony appearance varies according to the species, the age of the culture, and the mycological medium used. It is recommended for an accurate morphological study of <emphasis>Mucorales</emphasis> to use subculture at 27 to 30°C. Macroscopic examination involves the description of the colonies (height, color, texture) and the sporangiophore spatial branching configuration that can be observed under a 10× objective or a binocular loupe. For microscopic characteristics, a detailed study of adhesive tape mounts or teased mounts (a small piece of mycelium plus fruiting bodies placed in a water drop and gently needle teased) is essential for the description of the sporulating structures of the species. Fungi in the order <emphasis>Mucorales</emphasis> are characterized by branched, nonseptate, wide mycelia (10 to 20 μm) with chitinous walls. Sexual reproduction occurs by means of zygospore formation after fusion of hyphal branches from the same (homothallic) or from sexually differentiated mycelia (heterothallic) (<link linkend="ch0146s0000li0126">126</link>). The mature zygospore is often thick walled and undergoes an obligatory dormant period before germination. Asexual multiplication is by means of nonmotile sporangiospores (endospores) borne in closed sac-like structures named sporangia. They can exist as multispored sporangia or sporangiola (small sporangia) having few (or one) spores. Sporangia are supported by specialized hyphae named sporangiophores. In some species, they arise from a branched system of rhizoids, which anchor the sporangiophore to the substratum. These rhizoids are connected by a rooting branch called a stolon. Additional morphological structures are the columellae (central axis of the sporangium) and the apophysis (a swelling of the sporangiophore just below the columella). Some species can produce thick-walled and/or thin-walled swollen structures named chlamydospores and oidia, respectively. The liberation of sporangiospores occurs by breakage or deliquescence of the sporangial wall (<anchor id="ch0146s0000a0026"/><link linkend="ch0146s0000a0028">Fig. 1</link>).</para>
        <para id="ch0146s0000p0069">Structures of<emphasis>Mucorales</emphasis> used for routine identification include branching of sporangiophores, type of sporangia (merosporangia or sporangiola), shape, color, presence, or absence of apophyses and columellae, and presence or absence of rhizoids or chlamydospores. Several potentially useful websites are available: <ulink url="https://drfungus.org/">https://drfungus.org/</ulink>, <ulink url="http://www.mycology.adelaide.edu.au">www.mycology.adelaide.edu.au</ulink>, <ulink url="https://wi.knaw.nl/">https://wi.knaw.nl/</ulink>, and <ulink url="http://www.mycobank.org">http://www.mycobank.org</ulink>.</para>
        <anchor id="ch0146s0000a0027"/>
        <beginpage pagenum="2449"/>
        <figure id="ch0146s0000f0001"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0028"/><link linkend="ch0146s0000a0026"><emphasis role="strong">FIGURE 1</emphasis></link></phrase> Schematic drawing of morphological structures observed in <emphasis>Mucorales.</emphasis> Sporangiophores (A) bear sporangium-containing sporangiospores (D), can be anchored to the substrate by rhizoids (B), and expand by means of stolons (C). The columella (E) is produced at the apex of the sporangiophore, and in some species, an apophysis (G) is present. For some species, after liberation of sporangiospores, a thin sporangium membrane may be visible (F). Sporangia with a single or few spores are called sporangiola (H), and sporangia with few spores aligned in rows are called merosporangia (I). Thick-walled chlamydospores (J) and oidia (thin-walled swollen vesicles) (K) can be observed. Drawings by Dea Garcia-Hermoso.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0146f17.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0146s0015s0002">
        <title>Description of Specific Genera and Species</title>
        <anchor id="ch0146s0015a0003"/>
        <anchor id="ch0146s0000a0029"/>
        <para id="ch0146s0000p0070">Morphological (macroscopic and microscopic) characteristics of species frequently implicated in human infections are described below. Only major features are mentioned, from our own experience and from descriptions in specialized books (<link linkend="ch0146s0000li0016">16</link>, <link linkend="ch0146s0000li0022">22</link>, <link linkend="ch0146s0000li0127">127</link>). All colony morphology descriptions are made from subcultures on 2% malt extract agar (MEA) at 30°C (unless otherwise specified). The colonies of <emphasis>Mucorales</emphasis> have mostly floccose textures with colors varying from white (<emphasis>Saksenaea</emphasis>) to yellow (<emphasis>Mucor</emphasis>), brownish (<emphasis>Apophysomyces</emphasis>), or gray (<emphasis>Lichtheimia</emphasis> and <emphasis>Rhizomucor</emphasis>). The woolly brown-beige colonies of <emphasis>Actinomucor elegans</emphasis> are the exception. <emphasis>Rhizopus</emphasis> produces high aerial mycelium, whereas <emphasis>Rhizomucor</emphasis> produces a low aerial turf of 2- to 3-μm-high mycelium. The morphology of sporangiophores (height and branching) can vary depending on the genus. They can be branched, as in <emphasis>Lichtheimia</emphasis> or <emphasis>Mucor</emphasis>, irregularly branched, as in <emphasis>Rhizomucor</emphasis> and <emphasis>Actinomucor</emphasis>, or mostly unbranched, as in <emphasis>Rhizopus.</emphasis> In addition, the site from which the sporangiophore arises (between rhizoids or directly from the stolon) is a supplementary clue for the identification of the different genera (<anchor id="ch0146s0000a0030"/><link linkend="ch0146s0000a0032">Fig. 2</link>). A morphological key to the principal genera of <emphasis>Mucorales</emphasis> is illustrated in <anchor id="ch0146s0000a0031"/><link linkend="ch0146s0000a0033">Fig. 3</link>. The combination of asexual fruiting bodies and criteria such as maximum growth temperature is useful for the differentiation of these fungi to the species level. The phenotypic differences described below refer to species defined by nucleotide sequence analysis.</para>
        <figure id="ch0146s0000f0002"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0032"/><link linkend="ch0146s0000a0030"><emphasis role="strong">FIGURE 2</emphasis></link></phrase> Culture variability of some of the genera of <emphasis>Mucorales</emphasis> and their branching development.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0146f18.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <figure id="ch0146s0000f0003"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0033"/><link linkend="ch0146s0000a0031"><emphasis role="strong">FIGURE 3</emphasis></link></phrase> Flow diagram for the identification of the different genera of <emphasis>Mucorales</emphasis>.
</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0146f19.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <sect3 id="ch0146s0015s0001">
          <title>Family Lichtheimiaceae</title>
          <anchor id="ch0146s0015a0004"/>
          <anchor id="ch0146s0000a0034"/>
          <anchor id="ch0146s0000a0035"/>
          <para id="ch0146s0000p0071"><emphasis role="strong">Genus</emphasis> <emphasis><emphasis role="strong">Lichtheimia</emphasis></emphasis> <emphasis role="strong">Vuill. 1903 (formerly <emphasis>Absidia</emphasis> or <emphasis>Mycocladus</emphasis></emphasis>). The genus <emphasis>Absidia</emphasis> has been revised based on phylogenetic, physiological, and morphological characteristics (<link linkend="ch0146s0000li0009">9</link>). The thermotolerant species <emphasis>Absidia corymbifera, A. blakesleeana</emphasis>, and <emphasis>A. hyalospora</emphasis> were placed in the new family <emphasis>Mycocladiaceae</emphasis> and the genus <emphasis>Mycocladus.</emphasis> The same group suggested revision of the nomenclature rectification to create the family <emphasis>Lichtheimiaceae</emphasis> (instead of <emphasis>Mycocladiaceae</emphasis>) and the reassignment of the genus <emphasis>Lichtheimia</emphasis> in place of <emphasis>Mycocladus</emphasis> (<link linkend="ch0146s0000li0128">128</link>). The multigene sequence analysis of 38 isolates morphologically identified as <emphasis>Lichtheimia corymbifera</emphasis> uncovered the presence of a different species (named <emphasis>L. ramosa</emphasis>), which differs in morphology and nucleotide sequences from <emphasis>L. corymbifera</emphasis> (<link linkend="ch0146s0000li0008">8</link>). Of the five recognized species of the genus <emphasis>Lichtheimia</emphasis>, only <emphasis>L. corymbifera, L. ornata</emphasis>, and <emphasis>L. ramosa</emphasis> are of clinical relevance (<link linkend="ch0146s0000li0010">10</link>). These species seem to have a worldwide distribution and have been isolated from diverse substrates, including seeds, soil, and decaying vegetable debris. They produce white, fast-growing, woolly colonies, which become grayish brown with age. The maximum growth temperature is between 46°C and 52°C. <emphasis>L. ramosa</emphasis> differs from <emphasis>L. corymbifera</emphasis> and <emphasis>L. ornata</emphasis> by faster growth at high temperatures (<link linkend="ch0146s0000li0010">10</link>). Microscopically, sporangiophores are usually erect and highly branched and arise singly or in small corymbs from stolons, but they are not opposite the rhizoids as in <emphasis>Rhizopus.</emphasis> Rhizoids are present but generally indistinguishable. Multispored sporangia are small and spherical to pyriform. Columellae are hemispherical or ellipsoidal with a marked conical apophysis, and sporangiospores are smooth, hyaline, and ellipsoidal, cylindrical, or subglobose (2.73 by 2.24 μm in diameter) (<anchor id="ch0146s0000a0036"/><link linkend="ch0146s0000a0038">Fig. 4</link>). Giant cells of irregular shape are frequently present. The morphologies of sporangiophores and sporangiospores are very similar for the three pathogenic species, even though significant differences in the lengths, widths, and length-to-width ratios of the sporangiospores were previously reported (<link linkend="ch0146s0000li0055">55</link>).</para>
          <para id="ch0146s0000p0072"><emphasis role="strong">Genus <emphasis>Rhizomucor</emphasis> Lucet et Costantin 1900.</emphasis> <emphasis>Rhizomucor pusillus</emphasis> and <emphasis>R. miehei</emphasis> are the pathogenic species of the genus <emphasis>Rhizomucor.</emphasis> Species of the genus <emphasis>Rhizomucor</emphasis> are frequently isolated from composting or fermenting organic matter (<link linkend="ch0146s0000li0129">129</link>). Macroscopically, <emphasis>Rhizomucor</emphasis> produces rapidly growing gray (<emphasis>R. miehei</emphasis>) or brown (<emphasis>R. pusillus</emphasis>) woolly colonies. Sporangiophores are single or branched and arise from aerial mycelium or from stolons. Rhizoids are present but often difficult to recognize. Sporangia are multispored; apophyses are absent, and most species are thermophilic. Sporangiospores are round, hyaline, and smooth walled (<anchor id="ch0146s0000a0037"/><link linkend="ch0146s0000a0039">Fig. 5</link>). The species differ in the size of sporangia, sucrose assimilation, and the ability to grow in the presence of thiamine. <emphasis>R. miehei</emphasis> has smaller sporangia than <emphasis>R. pusillus</emphasis> (60 μm versus 100 μm in diameter) and fails to assimilate sucrose, and its growth depends on the presence of thiamine.</para>
          <figure id="ch0146s0000f0004"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0038"/><link linkend="ch0146s0000a0036"><emphasis role="strong">FIGURE 4</emphasis></link></phrase> <emphasis>Lichtheimia corymbifera.</emphasis> (A) Branched sporangiophores; (B) hemispheric columellae and sporangiospores; (C) pyriform multispored sporangium and marked conical apophysis; (D) sporangiospores.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f20.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
          <figure id="ch0146s0000f0005"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0039"/><link linkend="ch0146s0000a0037"><emphasis role="strong">FIGURE 5</emphasis></link></phrase> <emphasis>Rhizomucor pusillus.</emphasis> Sporangiophores with apical branching (A), simple rhizoids (B), and globose sporangia with round and smooth-walled sporangiospores (C and D) are shown.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f21.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
          <figure id="ch0146s0000f0006"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0040"/><link linkend="ch0146s0000a0043"><emphasis role="strong">FIGURE 6</emphasis></link></phrase> Micromorphology of <emphasis>Mucor circinelloides.</emphasis> (A) Sporangiophore; (B) sporangia; (B and C) ellipsoidal sporangiospores; (D) oidia.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f22.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
        </sect3>
        <sect3 id="ch0146s0015s0002">
          <title>Family Mucoraceae</title>
          <anchor id="ch0146s0015a0005"/>
          <anchor id="ch0146s0000a0041"/>
          <anchor id="ch0146s0000a0042"/>
          <para id="ch0146s0000p0073"><emphasis role="strong">Genus <emphasis>Mucor</emphasis> Fresen. 1850.</emphasis> Nine <emphasis>Mucor</emphasis> species are considered human pathogens: <emphasis>Mucor circinelloides, M. velutinosus, M. griseocyanus, M. janssenii, M. lusitanicus, M. irregularis</emphasis> (formerly <emphasis>R. variabilis</emphasis> var. <emphasis>variabilis</emphasis>), <emphasis>M. indicus, M. ramosissimus</emphasis>, and <emphasis>M. variicolumellatus</emphasis> (<link linkend="ch0146s0000li0012">12</link>, <link linkend="ch0146s0000li0130">130</link>, <link linkend="ch0146s0000li0131">131</link>).</para>
          <para id="ch0146s0000p0074">Colonies of the genus<emphasis>Mucor</emphasis> are usually fast growing and white to yellow, becoming gray with time. Tall sporangiophores (which can reach several centimeters in height) are simple or branched, supporting multispored nonapophysate sporangia. Sporangiospores are hyaline and subspherical to ellipsoidal. In some species, residues of the sporangial wall (collarette) can be present, and some species can produce rhizoids and chlamydospores (<anchor id="ch0146s0000a0043"/><link linkend="ch0146s0000a0040">Fig. 6</link>).</para>
          <para id="ch0146s0000p0075"><emphasis>Mucor circinelloides</emphasis> is a species complex historically comprising four formae: <emphasis>M. circinelloides</emphasis> f. <emphasis>circinelloides, M. circinelloides</emphasis> f. <emphasis>griseocyanus, M. circinelloides</emphasis> f. <emphasis>janssenii</emphasis>, and <emphasis>M. circinelloides</emphasis> f. <emphasis>lusitanicus.</emphasis> The differences between these formae rely mainly on the shape of columellae and sporangiospores. Recently, the revised taxonomy of the <emphasis>Mucor circinelloides</emphasis> species complex (MCSC), based on a combination of phenotypical and multilocus studies, revealed that the obsolete formae correspond to one or two discrete species (<link linkend="ch0146s0000li0131">131</link>).</para>
          <para id="ch0146s0000p0076">Major phenotypic differences within the thermotolerant<emphasis>Mucor</emphasis> species involved in human infections are summarized in <anchor id="ch0146s0000a0044"/><link linkend="ch0146s0000a0046">Table 2</link>. Maximum growth temperatures for pathogenic <emphasis>Mucor</emphasis> species range from 35°C (<emphasis>M. griseocyanus</emphasis>) to 42°C (<emphasis>M. indicus</emphasis>). The identification of these species can be complicated under unsuitable growth conditions, which can induce morphological variations such as sterile sporangia, swelling in sporangiophores, and modifications in size and shape of sporangia, columellae, and sporangiospores (<link linkend="ch0146s0000li0132">132</link>).</para>
          <para role="_-HD"><emphasis role="strong">Genus <emphasis>Actinomucor</emphasis> Schostak. 1898.</emphasis> The only species of the genus <emphasis>Actinomucor</emphasis> is <emphasis>Actinomucor elegans.</emphasis> This ubiquitous soil fungus has also been isolated from the rhizosphere of plants (oat, barley, and wheat) and from mouse and rabbit dung (<link linkend="ch0146s0000li0133">133</link>). The three varieties of this species (<emphasis>A. elegans</emphasis> var. <emphasis>elegans, A. elegans</emphasis> var. <emphasis>kuwaitiensis</emphasis>, and <emphasis>A. elegans</emphasis> var. <emphasis>taiwanensis</emphasis>) are now considered synonyms (<ulink url="http://www.indexfungorum.org">http://www.indexfungorum.org</ulink>). <emphasis>A. elegans</emphasis> is an emerging pathogen responsible for a few reported disseminated diseases (<link linkend="ch0146s0000li0134">134</link>–<link linkend="ch0146s0000li0136">136</link>) and superficial infections (<link linkend="ch0146s0000li0137">137</link>, <link linkend="ch0146s0000li0138">138</link>). This species is involved in the fermentation of a cheese-like soybean product (<emphasis>sufu</emphasis>) popular in Vietnam and China (<link linkend="ch0146s0000li0139">139</link>, <link linkend="ch0146s0000li0140">140</link>). Macroscopically, after 7 days of growth at 30°C, colonies are floccose and white to cream colored. They become brown-beige with a woolly texture in older cultures. The distinctive microscopic features of the genus <emphasis>Actinomucor</emphasis> facilitate the morphological identification. Hyaline, verticillately branched sporangiophores with varied lengths terminate in sporangia. Whorls of branched sporangiophores may give rise to secondary sporangia, or they can rebranch, terminating in subglobose columellae. The deliquescent wall of sporangia may be smooth or spiny, enclosing spherical to ovoidal sporangiospores measuring 5 to 10 μm in diameter. Rhizoids and chlamydospores are present (<anchor id="ch0146s0000a0045"/><link linkend="ch0146s0000a0047">Fig. 7</link>).</para>
          <table id="ch0146s0000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0146s0000a0046"/><link linkend="ch0146s0000a0044">TABLE 2</link></phrase></emphasis> Macroscopic and microscopic features in some <emphasis>Mucor</emphasis> species involved in human infection
</title>
            
            <tgroup cols="9">
              <tbody>
                <row>
                  <entry><phrase role="center">Species</phrase>
                  </entry>
                  <entry><phrase role="center">Colony morphology and maximum height (mm)</phrase>
                  </entry>
                  <entry><phrase role="center">Sporangiophore</phrase>
                  </entry>
                  <entry><phrase role="center">Maximum diam (μm) of sporangia</phrase>
                  </entry>
                  <entry><phrase role="center">Columella shape</phrase>
                  </entry>
                  <entry><phrase role="center">Sporangiospores</phrase>
                  </entry>
                  <entry><phrase role="center">Maximum growth temp (°C)</phrase>
                  </entry>
                  <entry><phrase role="center">Chlamydospores</phrase>
                  </entry>
                  <entry><phrase role="center">Other characteristics</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>M. circinelloides</emphasis>
                  </entry>
                  <entry>Light gray to brown; 6</entry>
                  <entry>Repeatedly branched</entry>
                  <entry>80</entry>
                  <entry>Obovoid to ellipsoidal</entry>
                  <entry>Ellipsoidal</entry>
                  <entry>36–40</entry>
                  <entry>Rare</entry>
                  <entry>Assimilation of ethanol</entry>
                </row>
                <row>
                  <entry><emphasis>M. velutinosus</emphasis>
                  </entry>
                  <entry>White-grayish; 2</entry>
                  <entry>Sympodially branched</entry>
                  <entry>60</entry>
                  <entry>Globose to conical</entry>
                  <entry>Verrucose, globose to subglobose</entry>
                  <entry>38</entry>
                  <entry>Abundant</entry>
                  <entry>Presence of rhizoids</entry>
                </row>
                <row>
                  <entry><emphasis>M. irregularis</emphasis> (formerly <emphasis>Rhizomucor variabilis</emphasis> var. <emphasis>variabilis</emphasis>)</entry>
                  <entry>White to yellowish; 2</entry>
                  <entry>Simple or once branched</entry>
                  <entry>100</entry>
                  <entry>Irregular shape</entry>
                  <entry>Variable shape</entry>
                  <entry>38</entry>
                  <entry>Abundant</entry>
                  <entry>Presence of rhizoids</entry>
                </row>
                <row>
                  <entry><emphasis>M. ramosissimus</emphasis>
                  </entry>
                  <entry>Olive gray; 2</entry>
                  <entry>Abundant swellings present</entry>
                  <entry>80; disposed on short lateral branches</entry>
                  <entry>Applanate</entry>
                  <entry>Smooth, subglobose to ellipsoidal</entry>
                  <entry>36</entry>
                  <entry>Absent</entry>
                  <entry>Presence of oidia in substrate mycelium</entry>
                </row>
                <row>
                  <entry><emphasis>M. indicus</emphasis>
                  </entry>
                  <entry>Deep yellow; 10</entry>
                  <entry>Repeatedly branched</entry>
                  <entry>75</entry>
                  <entry>Subglobose</entry>
                  <entry>Subglobose to cylindrical-ellipsoidal</entry>
                  <entry>42</entry>
                  <entry>Abundant</entry>
                  <entry>Light-dependent sporulation</entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <figure id="ch0146s0000f0007"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0047"/><link linkend="ch0146s0000a0045">FIGURE 7</link></phrase> <emphasis>Actinomucor elegans.</emphasis> Branched sporangiophores. (A) Subglobose columella (arrow); (B) whorl of branched sporangiophores with secondary sporangia (arrow); (C) verticillately branched sporangiophore.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f07.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
          <para id="ch0146s0000p0077"><emphasis role="strong">Genus <emphasis>Cokeromyces</emphasis> Shanor 1950.</emphasis> <emphasis>Cokeromyces recurvatus</emphasis> remains a rare agent of mucormycosis. It has been mostly recovered from soil or from rabbit, rat, or lizard dung in North America (United States and Mexico). Colonies are slow growing (less than 1 mm high) and grayish to brown. Microscopic features include the presence of long, recurved, twisted stalks arising from terminal vesicles of unbranched sporangiophores, globose sporangiola (8 to 11 μm in diameter) borne on those stalks, and smooth-walled spherical sporangiospores 2 to 4 μm in size (<anchor id="ch0146s0000a0049"/><link linkend="ch0146s0000a0052">Fig. 8</link>). A yeast-like form can be obtained by subculturing on media such as brain heart infusion or yeast extract peptone agar. Yeast-like forms are thin to thick walled and spherical, measuring 10 to 100 μm in diameter. Some cells produce single buds across their entire surface, producing a ship’s-wheel appearance similar to that of <emphasis>Paracoccidioides brasiliensis</emphasis> (<link linkend="ch0146s0000li0022">22</link>). The species is homothallic and produces lemon-shaped zygospores.</para>
          <anchor id="ch0146s0000a0048"/>
          <beginpage pagenum="2452"/>
        </sect3>
        <sect3 id="ch0146s0015s0003">
          <title>Family Saksenaeaceae</title>
          <anchor id="ch0146s0015a0006"/>
          <anchor id="ch0146s0000a0050"/>
          <para id="ch0146s0000p0078"><emphasis role="strong">Genus <emphasis>Apophysomyces</emphasis> P. C. Misra 1979.</emphasis> The members of the genus <emphasis>Apophysomyces</emphasis> are soil fungi with a tropical to subtropical distribution. They produce fast-growing white to gray colonies. General features are erect sporangiophores, unbranched and single, bearing multispored sporangia, usually pyriform, 20 to 60 μm in diameter. Columellae are hemispherical, cylindrical, trapezoidal, or ellipsoidal; the sporangiophores are smooth walled. The production of prominent vase-shaped, bell-shaped, or funnel-shaped apophyses is a distinctive feature of this species (<anchor id="ch0146s0000a0051"/><link linkend="ch0146s0000a0055">Fig. 9</link>). Good growth is observed at 42°C (<link linkend="ch0146s0000li0127">127</link>). The use of nutrient-poor media (water-yeast extract medium) can improve sporulation, often lacking on primary isolation media (<link linkend="ch0146s0000li0125">125</link>). Until recently, <emphasis>Apophysomyces</emphasis> was considered a monotypic genus with <emphasis>Apophysomyces elegans</emphasis> as the only species. The molecular diversity study performed by Alvarez and collaborators revealed three additional species (<emphasis>A. variabilis, A. trapeziformis</emphasis>, and <emphasis>A. ossiformis</emphasis>) of <emphasis>Apophysomyces</emphasis>, based on morphological, physiological, and phylogenetic differences (<link linkend="ch0146s0000li0011">11</link>). In addition, Bonifaz and collaborators (<link linkend="ch0146s0000li0141">141</link>) reported a primary cutaneous mucormycosis caused by a new species, <emphasis>Apophysomyces mexicanus</emphasis>, which mainly differed from the other species of the genus by the presence of verrucose sporangiophores and the intermediate spore shape between those of <emphasis>A. ossiformis</emphasis> and <emphasis>A. trapeziformis</emphasis>.</para>
          <para id="ch0146s0000p0079"><emphasis role="strong">Genus <emphasis>Saksenaea</emphasis> S. B. Saksena 1953.</emphasis> The genus <emphasis>Saksenaea</emphasis> is considered a complex of species. Alvarez et al. described two new species (<emphasis>Saksenaea erythrospora</emphasis> and <emphasis>S. oblongispora</emphasis>) different from <emphasis>S. vasiformis</emphasis>, long considered the only species in the genus (<link linkend="ch0146s0000li0142">142</link>). Similarly, a multilocus analysis based on ITS, large-subunit (LSU), and <emphasis>tef1</emphasis> nucleotide sequences confirmed two new species in the genus. The first one, <emphasis>Saksenaea trapezispora</emphasis>, was isolated from a cutaneous wound in a soldier (<link linkend="ch0146s0000li0143">143</link>). This species is closely related to <emphasis>S. oblongispora</emphasis> but exhibits moderately fast growth at 15°C and larger sporangiospores with a typical trapezoid shape, which differ from the other described species. The second species, <emphasis>Saksenaea loutrophoriformis</emphasis>, was described after ocular mucormycosis (<link linkend="ch0146s0000li0144">144</link>). It presents pale olive-brown sporangiospores and grows well at 15°C and up to 42°C.</para>
          <figure id="ch0146s0000f0008"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0052"/><link linkend="ch0146s0000a0049"><emphasis role="strong">FIGURE 8</emphasis></link></phrase> <emphasis>Cokeromyces recurvatus.</emphasis> (A and B) Mostly unbranched sporangiophores without rhizoids; (C) young sporangiolum; (D to F) recurved stalks arising from terminal vesicles and bearing few-spored sporangiola.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f23.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
          <para id="ch0146s0000p0080">Members of the genus<emphasis>Saksenaea</emphasis> are saprophytic fungi with a worldwide distribution first isolated from forest soil by Saksena (<link linkend="ch0146s0000li0018">18</link>). They produce white-grayish expanding colonies, with a maximum growth temperature of 44°C. The use of specific, nutrient-poor media (water-yeast extract medium) can induce sporulation, as suggested by Padhye and Ajello (<link linkend="ch0146s0000li0125">125</link>). Czapek medium at 30 or 37°C also induces sporulation. Microscopically, sporangiophores are unbranched with melanized rhizoids. The length of sporangiophore and sporangia, the shape and size of sporangiospores, and the maximum temperature for growth are useful parameters for the recognition of the different species. <anchor id="ch0146s0000a0054"/><link linkend="ch0146s0000a0058">Fig. 10</link> shows the distinctive flask-shaped multispored sporangia, which is a key feature for the identification of this genus.</para>
          <anchor id="ch0146s0000a0053"/>
          <beginpage pagenum="2453"/>
          <figure id="ch0146s0000f0009"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0055"/><link linkend="ch0146s0000a0051"><emphasis role="strong">FIGURE 9</emphasis></link></phrase> <emphasis>Apophysomyces elegans.</emphasis> (A to C) Unbranched sporangiophores (A) bearing multispored sporangia with a vase-shaped apophysis (B and C); (D) cylindrical sporangiospores.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f24.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
        </sect3>
        <sect3 id="ch0146s0015s0004">
          <title>Family Rhizopodaceae</title>
          <anchor id="ch0146s0015a0007"/>
          <anchor id="ch0146s0000a0056"/>
          <para id="ch0146s0000p0081"><emphasis role="strong">Genus <emphasis>Rhizopus</emphasis> Ehrenb. 1821.</emphasis> <emphasis>Rhizopus arrhizus</emphasis> var. <emphasis>arrhizus</emphasis> (syn., <emphasis>R. oryzae</emphasis>), <emphasis>R. arrhizus</emphasis> var. <emphasis>delemar</emphasis>, and <emphasis>Rhizopus microsporus</emphasis> are the most common pathogenic species. This genus, commonly found in the air, soil, and compost, is characterized by the rapid production of white cottony colonies, which turn brownish to black with time because of the presence of pigmented sporangiophores and sporangia. <anchor id="ch0146s0000a0057"/><link linkend="ch0146s0000a0059">Table 3</link> indicates useful features allowing the distinction between the pathogenic species of the genus <emphasis>Rhizopus.</emphasis> The sporangiophores are unbranched, arising singly or in groups, with well-developed rhizoids at the base, which distinguishes the genus <emphasis>Rhizopus</emphasis> from the genera <emphasis>Lichtheimia</emphasis> and <emphasis>Rhizomucor</emphasis>.</para>
          <figure id="ch0146s0000f0010"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0058"/><link linkend="ch0146s0000a0054"><emphasis role="strong">FIGURE 10</emphasis></link></phrase> <emphasis>Saksenaea vasiformis.</emphasis> (A and B) Unbranched sporangiophores with dark rhizoids and typical multispored flask-shaped sporangia.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f25.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
          <table id="ch0146s0000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0146s0000a0059"/><link linkend="ch0146s0000a0057">TABLE 3</link></phrase></emphasis> Main characteristics allowing distinction among <emphasis>Rhizopus</emphasis> species
</title>
            
            <tgroup cols="8">
              <tbody>
                <row>
                  <entry><phrase role="center">Species</phrase>
                  </entry>
                  <entry><phrase role="center">Sporangiophores (height)</phrase>
                  </entry>
                  <entry><phrase role="center">Sporangiospores (shape and ornamentation)</phrase>
                  </entry>
                  <entry><phrase role="center">Growth at temp</phrase>
                  </entry>
                </row>
                <row>
                  <entry><phrase role="center">30°C</phrase>
                  </entry>
                  <entry><phrase role="center">37°C</phrase>
                  </entry>
                  <entry><phrase role="center">40°C</phrase>
                  </entry>
                  <entry><phrase role="center">45°C</phrase>
                  </entry>
                  <entry><phrase role="center">50°C</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. arrhizus</emphasis> (syn., <emphasis>R. oryzae</emphasis>)</entry>
                  <entry>Often higher than 1 mm</entry>
                  <entry>Angular, round to ellipsoidal; striate</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. stolonifer</emphasis>
                  </entry>
                  <entry/>
                  <entry/>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. microsporus</emphasis> var. <emphasis>microsporus</emphasis></entry>
                  <entry>Not exceeding 0.8 mm</entry>
                  <entry>Angular ellipsoidal; striate</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. microsporus</emphasis> var. <emphasis>oligosporus</emphasis></entry>
                  <entry/>
                  <entry>Large, round; irregularly ornamented</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">Limited</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. microsporus</emphasis> var. <emphasis>rhizopodiformis</emphasis></entry>
                  <entry/>
                  <entry>Small, round; spinulose</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. microsporus</emphasis> var. <emphasis>chinensis</emphasis></entry>
                  <entry/>
                  <entry>Angular, homogeneous</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><para id="ch0146s0000p0082"><phrase role="center">+</phrase>
                    </para>
                    <para id="ch0146s0000p0083"><phrase role="center">(sporangia immature)</phrase>
                    </para>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. microsporus</emphasis> var. <emphasis>azygosporus</emphasis></entry>
                  <entry/>
                  <entry>Round; barely striate</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                </row>
                <row>
                  <entry><emphasis>R. schipperae</emphasis>
                  </entry>
                  <entry/>
                  <entry>Round to ellipsoidal; striate</entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">+</phrase>
                  </entry>
                  <entry><phrase role="center">Very limited</phrase>
                  </entry>
                  <entry><phrase role="center">Neg</phrase>
                  </entry>
                </row>
              </tbody>
            </tgroup>
          </table>
          <para id="ch0146s0000p0084">The microscopic features of<emphasis>R. arrhizus</emphasis> include single or clustered brown sporangiophores, of 1 to 2 mm in height, bearing multispored sporangia (150 to 170 μm in diameter). Columellae are ellipsoidal and brown to gray, and they generally have a truncate base. Rhizoids are well developed and easily observed under a stereomicroscope. Sporangiospores are angular and round to ellipsoidal, with longitudinal ridges 6 to 8 μm by 4.5 to 5.0 μm. Chlamydospores (10 to 35 μm in diameter) can be present (<anchor id="ch0146s0000a0061"/><link linkend="ch0146s0000a0063">Fig. 11</link>). This thermotolerant species can grow at 40°C but not at 45°C. <emphasis>R. arrhizus</emphasis> differs from the nonpathogenic species <emphasis>R. stolonifer</emphasis>, which harbors longer sporangiophores (&gt;2 mm) and larger columellae (up to 275 μm in diameter) and does not grow at 40°C (<link linkend="ch0146s0000li0145">145</link>).</para>
          <anchor id="ch0146s0000a0060"/>
          <beginpage pagenum="2454"/>
          <para id="ch0146s0000p0085">According to one recent U.S. epidemiological survey,<emphasis>R. microsporus</emphasis> is the second most frequent agent of mucormycosis (<link linkend="ch0146s0000li0146">146</link>). It can be isolated from soil or wood products. Colonies are pale brownish gray, with sporangiophores arising from stolons and measuring up to 400 μm in length (<link linkend="ch0146s0000li0147">147</link>). Sporangia are dark brown (up to 80 μm in diameter); columellae are conical, and sporangiospores are striate and angular to ellipsoidal (<anchor id="ch0146s0000a0062"/><link linkend="ch0146s0000a0064">Fig. 12</link>). The varieties of <emphasis>Rhizopus microsporus</emphasis> (<emphasis>R. microsporus</emphasis> var. <emphasis>microsporus, R. microsporus</emphasis> var. <emphasis>chinensis, R. microsporus</emphasis> var. <emphasis>oligosporus</emphasis>, and <emphasis>R. microsporus</emphasis> var. <emphasis>rhizopodiformis</emphasis>) can be distinguished on the basis of the morphology of sporangiospores and temperature tolerance (<link linkend="ch0146s0000li0148">148</link>). However, these differences observed between varieties are not supported genetically (<link linkend="ch0146s0000li0149">149</link>). <link linkend="ch0146s0000a0059">Table 3</link> indicates major differences among the species of the genus <emphasis>Rhizopus</emphasis>.</para>
          <figure id="ch0146s0000f0011"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0063"/><link linkend="ch0146s0000a0061"><emphasis role="strong">FIGURE 11</emphasis></link></phrase> Typical microscopic features of <emphasis>Rhizopus arrhizus.</emphasis> (A) Melanized sporangiophore arising opposite rhizoids; (B) striate angular sporangiospores.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f11.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
          <figure id="ch0146s0000f0012"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0064"/><link linkend="ch0146s0000a0062"><emphasis role="strong">FIGURE 12</emphasis></link></phrase> Short pigmented sporangiophores arising in pairs in <emphasis>Rhizopus microsporus.</emphasis> (A and C) Rhizoids; (B) conical columella; (D) chlamydospores.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f12.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
        </sect3>
        <sect3 id="ch0146s0015s0005">
          <title>Family Cunninghamellaceae</title>
          <anchor id="ch0146s0015a0008"/>
          <anchor id="ch0146s0000a0065"/>
          <para id="ch0146s0000p0086"><emphasis role="strong">Genus <emphasis>Cunninghamella</emphasis> Matr. 1903.</emphasis> Traditionally, <emphasis>Cunninghamella bertholletiae</emphasis> was considered the only clinically relevant species of the genus. Although rarely involved in human disease, <emphasis>C. bertholletiae</emphasis> has the capacity to infect immunocompetent individuals. Other species, such as <emphasis>C. elegans, C. echinulata</emphasis> (<link linkend="ch0146s0000li0150">150</link>), and more recently <emphasis>C. blakesleeana</emphasis> (<link linkend="ch0146s0000li0151">151</link>), have also been implicated in cases of human mucormycoses. <emphasis>C. bertholletiae</emphasis> is a thermotolerant fungus isolated from soil. It produces white to dark gray expanding colonies. Sporangiophores are erect with lateral branching at the apical zone. Each branch produces a globose vesicle (up to 40 μm in diameter), which bears 1-spored sporangiola. At maturity, each sporangiolum will become a finely echinulate spherical sporangiospore (7 to 11 μm in diameter) (<anchor id="ch0146s0000a0066"/><link linkend="ch0146s0000a0067">Fig. 13</link>). Key features for the identification of <emphasis>C. bertholletiae</emphasis> are essentially its growth at 45°C (with a maximum of 50°C) and the presence of monosporic sporangiola borne on terminal vesicles.</para>
          <figure id="ch0146s0000f0013"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0067"/><link linkend="ch0146s0000a0066"><emphasis role="strong">FIGURE 13</emphasis></link></phrase> <emphasis>Cunninghamella bertholletiae.</emphasis> (A to D) Development of single-spored sporangiola on the surface of globose vesicles (A, B, and D), with frequent apical branching (C); (E) mature sporangiola grow to be single echinulate sporangiospores; (F) rhizoids.
</title>
            
            <mediaobject>
              <imageobject>
                <imagedata fileref="Ch0146f26.jpg" width="100%" scalefit="1"/>
              </imageobject>
            </mediaobject>
          </figure>
        </sect3>
        <sect3 id="ch0146s0015s0006">
          <title>Family Syncephalastraceae</title>
          <anchor id="ch0146s0015a0009"/>
          <anchor id="ch0146s0000a0068"/>
          <anchor id="ch0146s0000a0069"/>
          <para id="ch0146s0000p0087"><emphasis role="strong">Genus <emphasis>Syncephalastrum</emphasis> J. Schröt. 1886.</emphasis> Species in the genus <emphasis>Syncephalastrum</emphasis> have a worldwide distribution and have been isolated from soil, plants, and diverse foodstuffs (<link linkend="ch0146s0000li0018">18</link>). The only species associated with cases of human infection is <emphasis>Syncephalastrum racemosum</emphasis>, which is described below.</para>
          <para id="ch0146s0000p0088">In culture,<emphasis>S. racemosum</emphasis> grows rapidly and produces expanding white-grayish colonies, which turn darker due to the formation of sporangia and resemble the colonies formed by <emphasis>Rhizopus</emphasis> spp. The maximum temperature for growth is 40°C. Sporangiophores are short, erect, and mostly branched, arising from rhizoids and forming terminal globose vesicles. The whole surface of these vesicles is covered with cylindrical merosporangia containing (3 to 14) smooth-walled, spherical to ovoid merospores arranged in single rows (<anchor id="ch0146s0000a0070"/><link linkend="ch0146s0000a0072">Fig. 14</link>). This is a distinctive feature of the genus compared to other members of <emphasis>Mucorales</emphasis>.</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0146s0016">
      <title>■ Molecular Identification</title>
      <anchor id="ch0146s0016a0001"/>
      <anchor id="ch0146s0000a0071"/>
      <para id="ch0146s0000p0089">The species identification of<emphasis>Mucorales</emphasis> by phenotypic methods remains a difficult task because of the common morphological features among the members of this group. In addition, some pathogenic species, such as members of <emphasis>S. vasiformis</emphasis> species complex and <emphasis>Apophysomyces elegans</emphasis> species complex, regularly fail to sporulate on standard mycological media (<link linkend="ch0146s0000li0152">152</link>). Therefore, sequence-based identification is of interest because it provides fast and easily comparable data (<link linkend="ch0146s0000li0153">153</link>). In search of reliable DNA barcode markers for <emphasis>Fungi</emphasis>, Schoch and collaborators compared the performance of six markers: three nuclear ribosomal regions (ITS, ribosomal large subunit, and ribosomal small subunit) and portions of three protein-coding genes in 17 fungal lineages. The ITS was finally proposed as the primary fungal barcode across all groups (<link linkend="ch0146s0000li0154">154</link>). A large phylogenetic study (more than 650 strains) validated the ITS marker as a useful barcode for the identification of <emphasis>Mucorales.</emphasis> Most of the accepted species that are currently taxonomically defined by morphology were well discriminated. However, the identity threshold of 99% defined by Balajee et al. in 2009 (<link linkend="ch0146s0000li0155">155</link>) did not cover the intraspecific variability of the clinically important species tested (<link linkend="ch0146s0000li0149">149</link>). Additional phylogenetic studies to delimit species boundaries and the analysis of intraspecies and interspecies variations are needed to define a new identity threshold to establish a reliable ITS-based identification for these organisms. Recently, the single-copy marker <emphasis>cfs</emphasis>, encoding a cyclopropane fatty acyl-phospholipid synthase, proved to be a useful standard marker specific for <emphasis>Mucorales</emphasis> (<link linkend="ch0146s0000li0131">131</link>).</para>
      <figure id="ch0146s0000f0014"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0072"/><link linkend="ch0146s0000a0070"><emphasis role="strong">FIGURE 14</emphasis></link></phrase> Short sporangiophores arising from rhizoids (A), terminal vesicles covered by merosporangia (B, C, and E), and merospores (D) characteristic of <emphasis>Syncephalastrum racemosum</emphasis>.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0146f27.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <sect2 id="ch0146s0016s0001">
        <title>Typing Systems</title>
        <anchor id="ch0146s0016a0002"/>
        <anchor id="ch0146s0000a0073"/>
        <para id="ch0146s0000p0090">By definition, typing methods are developed to study the diversity and relatedness of isolates (environmental or clinical isolates) within a given species. Few methods have been evaluated for the typing of clinical isolates of<emphasis>Mucorales</emphasis> (<link linkend="ch0146s0000li0032">32</link>, <link linkend="ch0146s0000li0156">156</link>, <link linkend="ch0146s0000li0157">157</link>). These methods proved to be inefficient because of their low discriminatory power. Recently, a multilocus microsatellite genotyping method for <emphasis>Rhizopus arrhizus</emphasis> was applied to a small number of isolates, revealing a high degree of discrimination (<emphasis>D</emphasis>value, 0.989) when a combination of six markers was used (<link linkend="ch0146s0000li0158">158</link>). However, the study lacks data on specificity with closely <emphasis>R. arrhizus</emphasis>-related species and a larger sampling of clinical isolates. Whole-genome sequencing may provide the key to designing efficient typing methods in the future (<link linkend="ch0146s0000li0122">122</link>, <link linkend="ch0146s0000li0159">159</link>). This is a rapid approach to identifying single nucleotide polymorphisms (SNPs) for noninvestigated species’ genomes. It has been proved to be useful in the investigation of <emphasis>Mucor circinelloides</emphasis> outbreaks. The analysis of full-genome sequences of 21 strains of <emphasis>M. circinelloides</emphasis> isolated from burn patients and environmental isolates recovered from the hospital burn unit revealed different genotypes, suggesting cross transmission between the patients and several contaminated sources (<link linkend="ch0146s0000li0160">160</link>).</para>
        <anchor id="ch0146s0000a0074"/>
        <beginpage pagenum="2456"/>
      </sect2>
      <sect2 id="ch0146s0016s0002">
        <title>Serologic Tests</title>
        <anchor id="ch0146s0016a0003"/>
        <anchor id="ch0146s0000a0075"/>
        <para id="ch0146s0000p0091">No commercial assays are available at this time. However, a<emphasis>Mucorales</emphasis> antigen can be used to detect <emphasis>Mucorales</emphasis>-specific T cells (<link linkend="ch0146s0000li0161">161</link>). This test has been proposed as a diagnostic test for detection of <emphasis>Mucorales</emphasis>-specific T cells in patients (<emphasis>n</emphasis> = 3) with invasive mucormycoses and not patients with other types of infection (<emphasis>n</emphasis> = 17) or without infection (<emphasis>n</emphasis> = 8). These T cells were detectable at the onset and during the disease but not before diagnosis.</para>
      </sect2>
      <sect2 id="ch0146s0016s0003">
        <title>Antifungal Susceptibilities</title>
        <anchor id="ch0146s0016a0004"/>
        <anchor id="ch0146s0000a0076"/>
        <para id="ch0146s0000p0092"><emphasis>In vitro</emphasis> antifungal susceptibility can be evaluated by the reference microdilution broth techniques from the CLSI (<link linkend="ch0146s0000li0162">162</link>) and the EUCAST (<link linkend="ch0146s0000li0163">163</link>) or, alternatively, by a commercially available test (Etest) (<link linkend="ch0146s0000li0164">164</link>). Although <emphasis>Mucorales</emphasis> share most antifungal susceptibility patterns, there is some specificity depending on genus and even species. AmB is the most active drug against the majority of <emphasis>Mucorales</emphasis>, as shown both <emphasis>in vitro</emphasis> (<link linkend="ch0146s0000li0100">100</link>, <link linkend="ch0146s0000li0165">165</link>–<link linkend="ch0146s0000li0171">171</link>) and in animal models of infection (<link linkend="ch0146s0000li0172">172</link>–<link linkend="ch0146s0000li0176">176</link>). Among the new azoles, voriconazole has poor activity (<link linkend="ch0146s0000li0170">170</link>), which is highlighted by breakthrough mucormycosis in patients treated with voriconazole (<link linkend="ch0146s0000li0177">177</link>) and in experimental models (<link linkend="ch0146s0000li0178">178</link>). In contrast, posaconazole has relatively low MICs (<link linkend="ch0146s0000li0100">100</link>, <link linkend="ch0146s0000li0166">166</link>, <link linkend="ch0146s0000li0167">167</link>, <link linkend="ch0146s0000li0170">170</link>, <link linkend="ch0146s0000li0176">176</link>, <link linkend="ch0146s0000li0179">179</link>), and its <emphasis>in vivo</emphasis> efficacy has been demonstrated as curative and prophylactic treatment in animal models (<link linkend="ch0146s0000li0180">180</link>, <link linkend="ch0146s0000li0181">181</link>). Isavuconazole has higher MICs than posaconazole (<link linkend="ch0146s0000li0170">170</link>, <link linkend="ch0146s0000li0182">182</link>), with values being in general one to three steps higher than those for posaconazole (<link linkend="ch0146s0000li0183">183</link>). However, animal models suggest that isavuconazole is effective as prophylaxis or curative treatment (<link linkend="ch0146s0000li0184">184</link>). Echinocandins have no significant <emphasis>in vitro</emphasis> activity (<link linkend="ch0146s0000li0185">185</link>, <link linkend="ch0146s0000li0186">186</link>), even though <emphasis>Rhizopus arrhizus</emphasis> possesses the target enzyme for this class of compounds. <emphasis>In vivo</emphasis>, caspofungin alone exhibits modest efficacy (<link linkend="ch0146s0000li0077">77</link>), and it showed promising clinical efficacy in combination with AmB in some patients (<link linkend="ch0146s0000li0132">132</link>).</para>
      </sect2>
      <sect2 id="ch0146s0016s0004">
        <title>Evaluation, Interpretation, and Reporting of Results</title>
        <anchor id="ch0146s0016a0005"/>
        <anchor id="ch0146s0000a0077"/>
        <para id="ch0146s0000p0093">Culture results should always be interpreted in light of the clinical presentation and along with the results of direct examination and/or histopathology. A positive culture of<emphasis>Mucorales</emphasis> can be due to contamination during collection of the sample or processing of the sample in the laboratory. A study in Spain showed that less than 8% of the <emphasis>Mucorales</emphasis> isolates recovered in the laboratory were from patients with invasive mucormycosis (<link linkend="ch0146s0000li0040">40</link>, <link linkend="ch0146s0000li0187">187</link>). In the revised definitions of the EORTC/MSG study group for the diagnosis of invasive fungal infections, proven disease requires that “histopathologic, cytopathologic, or direct microscopic examination of a specimen obtained by needle aspiration or biopsy shows hyphae accompanied by evidence of associated tissue damage” or “the recovery of a mould by culture of a specimen obtained by a sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with an infectious disease process, excluding bronchoalveolar lavage fluid, a cranial sinus cavity specimen, and urine” (<link linkend="ch0146s0000li0188">188</link>). However, “the failure to meet the criteria for invasive fungal infection does not mean that there is none, only that there is insufficient evidence to support the diagnosis. This is the most compelling reason for not employing these definitions in daily clinical practice.” One may thus have proof of an invasive fungal infection and a high suspicion of mucormycosis without evidence of the latter in the absence of positive culture. As mentioned above, attempts to establish the definite diagnosis are important to offer the best management for the patient.</para>
      </sect2>
      <sect2 id="ch0146s0016s0005">
        <title>ENTOMOPHTHOROMYCOSIS</title>
        <anchor id="ch0146s0016a0006"/>
        <anchor id="ch0146s0000a0078"/>
      </sect2>
    </sect1>
    <sect1 id="ch0146s0017">
      <title>Epidemiology and Transmission</title>
      <anchor id="ch0146s0017a0001"/>
      <anchor id="ch0146s0000a0079"/>
      <para id="ch0146s0000p0094">Most members of the<emphasis>Entomophthoromycota</emphasis> are pathogens of arthropods and other animals. They are present in soil, decaying vegetables, and dung worldwide but more abundantly in the warm climates of Africa and Asia (<link linkend="ch0146s0000li0022">22</link>). Infections due to <emphasis>Basidiobolus ranarum</emphasis> are described in Asia (Indonesia [where the first cases were described], India, and Myanmar) and in several African countries (mostly Uganda and Nigeria but also Togo, Ghana, Cameroon, and Benin, as well as Saudi Arabia) but rarely in South America. <emphasis>B. ranarum</emphasis> has recently emerged with gastrointestinal presentations in the United States (<link linkend="ch0146s0000li0189">189</link>). Infections due to <emphasis>Conidiobolus</emphasis> spp. are described in Africa, Madagascar, Mayotte, India, China, Japan, and South America (<link linkend="ch0146s0000li0190">190</link>–<link linkend="ch0146s0000li0192">192</link>).</para>
    </sect1>
    <sect1 id="ch0146s0018">
      <title>Clinical Manifestations</title>
      <anchor id="ch0146s0018a0001"/>
      <anchor id="ch0146s0000a0080"/>
      <para id="ch0146s0000p0095">One of the major differences between mucormycosis and entomophthoromycosis is that the former occurs mainly in predisposed individuals, whereas the latter occurs mostly in apparently immunocompetent hosts.</para>
      <para id="ch0146s0000p0096"><emphasis>B. ranarum</emphasis> is responsible for subcutaneous infections that mostly affect the limbs, buttocks, trunk, and perineum and less often the face and neck. The disease presents mostly in male children as a woody, hard, brawny, painless nodule that enlarges peripherally without affecting the overlying skin (<link linkend="ch0146s0000li0193">193</link>). Sporadic invasive infections with gastrointestinal involvement in adults (<link linkend="ch0146s0000li0189">189</link>, <link linkend="ch0146s0000li0194">194</link>) and children (<link linkend="ch0146s0000li0195">195</link>) have been described worldwide. Of note, a small cluster has also been reported in Arizona (<link linkend="ch0146s0000li0196">196</link>), and such presentation may mimic malignancies (<link linkend="ch0146s0000li0197">197</link>–<link linkend="ch0146s0000li0199">199</link>). Disseminated infections are extremely rare (<link linkend="ch0146s0000li0200">200</link>).</para>
      <para id="ch0146s0000p0097">In contrast to basidiobolomycosis, infections due to<emphasis>Conidiobolus</emphasis> spp. affect adults (mostly males) and outdoor workers and are usually limited to the nose and face. The onset of the infection is thought to take place in the nasal mucosa after inoculation of spores following a minor trauma. Swelling extends locally to the nose, the nasolabial folds, cheeks, eyebrows, the upper lip, and even the palate and pharynx, producing the characteristic facies in severe forms (<link linkend="ch0146s0000li0201">201</link>). A clinical staging system has now been proposed, split into atypical, early, intermediate, and late disease (<link linkend="ch0146s0000li0202">202</link>). Conjunctival inoculation of the fungus was documented once in Brazil (<link linkend="ch0146s0000li0203">203</link>). Rare cases of dissemination in immunosuppressed individuals have been reported (<link linkend="ch0146s0000li0204">204</link>). Tissue lesions caused by <emphasis>C. coronatus</emphasis> and <emphasis>C. incongruus</emphasis> are similar (<link linkend="ch0146s0000li0205">205</link>).</para>
      <anchor id="ch0146s0000a0081"/>
      <beginpage pagenum="2457"/>
    </sect1>
    <sect1 id="ch0146s0019">
      <title>Treatment and Outcome</title>
      <anchor id="ch0146s0019a0001"/>
      <anchor id="ch0146s0000a0082"/>
      <para id="ch0146s0000p0098">Therapeutic strategies for basidiobolomycosis and conidiobolomycosis are not standardized because of the lack of clinical trials for these rare infections. Surgical excision, potassium iodide, and prolonged azole therapy have been used successfully for infection due to<emphasis>Basidiobolus</emphasis> (<link linkend="ch0146s0000li0034">34</link>, <link linkend="ch0146s0000li0190">190</link>). For infections due to <emphasis>Conidiobolus</emphasis> spp., potassium iodide was historically used, with variable results. Prolonged oral azole therapy should now be used and is successful (<link linkend="ch0146s0000li0191">191</link>). More recently, a combination of itraconazole and potassium iodide has provided encouraging results, with 7 of 10 patients responding to the combination, including five patients with complete resolution (<link linkend="ch0146s0000li0206">206</link>).</para>
    </sect1>
    <sect1 id="ch0146s0020">
      <title>Collection, Transport, and Storage of Specimens</title>
      <anchor id="ch0146s0020a0001"/>
      <anchor id="ch0146s0000a0083"/>
      <para id="ch0146s0000p0099">As several differential diagnoses are possible, a confirmation of the fungal agent should be obtained; tissue biopsy specimens of the affected area are the best diagnostic specimens. The diagnosis relies on classical procedures combining direct examination and culture in unfixed samples and/or histology in fixed samples. In the gastrointestinal form of basidiobolomycosis, biopsy specimens obtained during endoscopy are the gold standard. Specimens should be processed immediately and should not be refrigerated (<link linkend="ch0146s0000li0193">193</link>).</para>
    </sect1>
    <sect1 id="ch0146s0021">
      <title>Direct Examination</title>
      <anchor id="ch0146s0021a0001"/>
      <anchor id="ch0146s0000a0084"/>
      <para id="ch0146s0000p0100">Direct examination of fresh specimens can be performed after dissolution of the tissue sample in KOH and staining with calcofluor white. For histology, classical stains, including hematoxylin and eosin, periodic acid-Schiff, and Grocott-Gomori, can be used. Typically, hyphae are broad, thin walled, and generally more septate than those of the<emphasis>Mucorales.</emphasis> Simultaneous acute and chronic inflammatory reactions are observed in the affected tissue. Hyphae can be observed with routine staining procedures. The presence of a Splendore-Hoeppli reaction associated with typical hyphae in tissue sections stained with hematoxylin-eosin is highly suggestive of entomophthoromycosis. The pink structure corresponds to a sheath of amorphous eosinophilic material around hyphal fragments. Although the presence of a Splendore-Hoeppli phenomenon is strongly suggestive of entomophthoromycosis, it can be observed in various bacterial, fungal, and parasitic infections as well as in noninfectious diseases (<link linkend="ch0146s0000li0207">207</link>). In contrast to mucormycosis, there is typically no necrosis and no invasion of blood vessels.</para>
    </sect1>
    <sect1 id="ch0146s0022">
      <title>Antigen Detection</title>
      <anchor id="ch0146s0022a0001"/>
      <anchor id="ch0146s0000a0085"/>
      <para id="ch0146s0000p0101">No antigen tests are currently available for the detection of entomophthoromycosis.</para>
    </sect1>
    <sect1 id="ch0146s0023">
      <title>Detection of Nucleic Acids in Clinical Materials</title>
      <anchor id="ch0146s0023a0001"/>
      <anchor id="ch0146s0000a0086"/>
      <para id="ch0146s0000p0102">A PCR-based technique targeting<emphasis>Basidiobolus</emphasis> has been developed for the diagnosis of entomophthoromycosis in human samples (<link linkend="ch0146s0000li0208">208</link>).</para>
    </sect1>
    <sect1 id="ch0146s0024">
      <title>Isolation Procedures</title>
      <anchor id="ch0146s0024a0001"/>
      <anchor id="ch0146s0000a0087"/>
      <para id="ch0146s0000p0103">Biopsy samples should be sliced or minced (not ground) and placed on Sabouraud agar or PDA. Media containing cycloheximide should be avoided because of inhibition of<emphasis>Basidiobolus</emphasis> and <emphasis>Conidiobolus</emphasis> growth. Cultures must be incubated at both 37°C and 25 to 30°C because of the various optimum growth temperatures of these organisms. <emphasis>Basidiobolus</emphasis> grows well at 30°C but less rapidly at 37°C, whereas <emphasis>Conidiobolus</emphasis> spp. grow rapidly at 37°C (<link linkend="ch0146s0000li0018">18</link>).</para>
    </sect1>
    <sect1 id="ch0146s0025">
      <title>Identification</title>
      <anchor id="ch0146s0025a0001"/>
      <anchor id="ch0146s0000a0088"/>
    </sect1>
    <sect1 id="ch0146s0026">
      <title>■ Phenotypic Identification</title>
      <anchor id="ch0146s0026a0001"/>
      <anchor id="ch0146s0000a0089"/>
      <para id="ch0146s0000p0104">Members of<emphasis>Entomophthoromycota</emphasis> are characterized by the presence of coenocytic hyphae or short hyphal bodies and of primary and secondary conidia, which can be forcibly discharged at maturity. Primary conidia with papillate bases are produced straight from the thallus in repetitive cycles (<link linkend="ch0146s0000li0016">16</link>). They generate a germ tube or can produce smaller secondary conidia (similar in morphology to the primary conidia) in the presence of suitable substrate conditions. Villose conidia (old conidia with hair-like appendages) can also develop. Passive release of microconidia may also occur. In some species, thin sporangiophores bear capilliconidia at their apex. These spores are characterized by an adhesive tip. Zygospores (thick, bilayered, walled spores) are produced after conjugation of undifferentiated gametangia and can have beak-like appendages coming from gametangial remains (<link linkend="ch0146s0000li0016">16</link>, <link linkend="ch0146s0000li0022">22</link>, <link linkend="ch0146s0000li0127">127</link>). Sporulation occurs after 3 to 10 days of culture. Colonies are usually waxy or powdery with radial folds and with colors ranging from white to tan-brown (<link linkend="ch0146s0000li0016">16</link>, <link linkend="ch0146s0000li0022">22</link>). A key feature of these fungi is their capacity to forcibly discharge conidia. Therefore, placing a cover slide inside the petri dish lid can be helpful to recover the papillate conidia. For a detailed description and additional information, see the taxonomic classification study by Ben-Ze’ev and Kenneth (<link linkend="ch0146s0000li0209">209</link>).</para>
      <figure id="ch0146s0000f0015"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0090"/><link linkend="ch0146s0000a0094"><emphasis role="strong">FIGURE 15</emphasis></link></phrase> <emphasis>Conidiobolus coronatus.</emphasis> (A) Ten-day-old powdery colony on PDA medium; (B) primary conidia with papilla; (C) passively released secondary conidium (arrow); (D) villose conidium.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0146f15.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <sect2 id="ch0146s0026s0001">
        <title>Class Entomophthoromycetes, Order Entomophthorales</title>
        <anchor id="ch0146s0026a0002"/>
        <anchor id="ch0146s0000a0091"/>
        <anchor id="ch0146s0000a0092"/>
        <sect3 id="ch0146s0026s0001">
          <title>Family Ancylistaceae</title>
          <anchor id="ch0146s0026a0003"/>
          <anchor id="ch0146s0000a0093"/>
          <para id="ch0146s0000p0105"><emphasis role="strong">Genus <emphasis>Conidiobolus</emphasis> Bref. 1884.</emphasis> The genus <emphasis>Conidiobolus</emphasis> includes saprobes and facultative pathogens of invertebrates and vertebrates (<link linkend="ch0146s0000li0015">15</link>). The three species causing human conidiobolomycosis are <emphasis>C. coronatus, C. incongruus</emphasis>, and <emphasis>C. lamprauges</emphasis>.</para>
          <para id="ch0146s0000p0106"><emphasis>Conidiobolus coronatus</emphasis> is a fast-growing fungus present in soil and on decaying leaves (<link linkend="ch0146s0000li0127">127</link>). It is most frequently isolated in the tropical forests of Africa (<link linkend="ch0146s0000li0210">210</link>). <emphasis>C. coronatus</emphasis> is an occasional pathogen of insects and has been recovered from diverse animals such as dolphins, chimpanzees, and horses (<link linkend="ch0146s0000li0018">18</link>).</para>
          <para id="ch0146s0000p0107">Colonies are hyaline, radially folded, with an initially waxy appearance, becoming powdery when mycelia become visible. The inside of the lid of the dish can be covered with conidia forcibly discharged by the conidiophores. These primary conidia are spherical (40 μm in diameter) and possess a prominent papilla. Villose conidia are present in older cultures (<anchor id="ch0146s0000a0094"/><link linkend="ch0146s0000a0090">Fig. 15</link>). Replicative, passively discharged microconidia are regularly produced (<link linkend="ch0146s0000li0016">16</link>). <emphasis>C. coronatus</emphasis> can be differentiated from the two other pathogenic species by the absence of zygospores on PDA medium and the presence of villose conidia. Similarly, <emphasis>C. incongruus</emphasis> produces zygospores, which differ from those of <emphasis>C. lamprauges</emphasis> by the size and the formation of small globules inside the mature zygospores (<link linkend="ch0146s0000li0211">211</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0146s0026s0002">
        <title>Order Basidiobolales</title>
        <anchor id="ch0146s0026a0004"/>
        <anchor id="ch0146s0000a0095"/>
        <sect3 id="ch0146s0026s0002">
          <title>Family Basidiobolaceae</title>
          <anchor id="ch0146s0026a0005"/>
          <anchor id="ch0146s0000a0096"/>
        </sect3>
        <sect3 id="ch0146s0026s0003">
          <title>Genus Basidiobolus.</title>
          <anchor id="ch0146s0026a0006"/>
          <anchor id="ch0146s0000a0097"/>
          <para id="ch0146s0000p0108"><emphasis>BASIDIOBOLUS RANARUM EIDEM</emphasis>. <emphasis>Basidiobolus ranarum</emphasis> is present in decaying fruit and vegetable matter (<link linkend="ch0146s0000li0127">127</link>). It can be present as a commensal in the intestinal tracts of amphibians and reptiles (<link linkend="ch0146s0000li0212">212</link>). Colonies on PDA are yellowish and waxy, have radial folds, and do not form aerial mycelium when young. They grow well at 25 to 37°C. Microscopic examination after 7 to 10 days of culture reveals large aseptate mycelia, which can break up into free hyphal elements that are basically uninucleate. <emphasis>B. ranarum</emphasis> is homothallic. Sexual reproduction occurs by gametangial conjugation, producing thick-walled zygospores with lateral protuberances of gametangial remains (beaks) (<anchor id="ch0146s0000a0098"/><link linkend="ch0146s0000a0103">Fig. 16</link>). Primary conidiophores with swollen apices forcibly discharge spherical primary conidia. Secondary conidia are pyriform (clavate) and are passively released from the sporophore. These conidia possess a knob-like adhesive tip. Occasionally, elongated cells with a terminal adhesive tip (capilliconidia) are present (<link linkend="ch0146s0000li0016">16</link>, <link linkend="ch0146s0000li0210">210</link>).</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0146s0027">
      <title>■ Molecular Identification</title>
      <anchor id="ch0146s0027a0001"/>
      <anchor id="ch0146s0000a0099"/>
      <para id="ch0146s0000p0109">There is no standardized technique published for the molecular identification of<emphasis>Entomophthoromycota</emphasis>.</para>
    </sect1>
    <sect1 id="ch0146s0028">
      <title>Typing Systems</title>
      <anchor id="ch0146s0028a0001"/>
      <anchor id="ch0146s0000a0100"/>
      <para id="ch0146s0000p0110">To date, there is no typing method developed for<emphasis>Entomophthoromycota</emphasis>.</para>
    </sect1>
    <sect1 id="ch0146s0029">
      <title>Serologic Tests</title>
      <anchor id="ch0146s0029a0001"/>
      <anchor id="ch0146s0000a0101"/>
      <para id="ch0146s0000p0111">There are no commercially available diagnostic tests.</para>
    </sect1>
    <sect1 id="ch0146s0030">
      <title>Antifungal Susceptibilities</title>
      <anchor id="ch0146s0030a0001"/>
      <anchor id="ch0146s0000a0102"/>
      <para id="ch0146s0000p0112"><emphasis>In vitro</emphasis> susceptibility data are scarce, and some technical issues (such as inoculum preparation) remain to be addressed. Potassium iodide shows no <emphasis>in vitro</emphasis> activity despite <emphasis>in vivo</emphasis> efficacy (<link linkend="ch0146s0000li0213">213</link>). Both <emphasis>Conidiobolus</emphasis> and <emphasis>Basidiobolus</emphasis> species exhibit relatively high MICs when tested with AmB, azoles, and echinocandins (<link linkend="ch0146s0000li0214">214</link>–<link linkend="ch0146s0000li0216">216</link>). Recently, Tondolo and colleagues reported terbinafine as an active drug against <emphasis>C. lamprauges</emphasis> (<link linkend="ch0146s0000li0216">216</link>). Overall, <emphasis>Basidiobolus</emphasis> spp. are more susceptible than <emphasis>Conidiobolus</emphasis> spp. to the different antifungals tested.</para>
      <figure id="ch0146s0000f0016"><title><phrase role="figureLabel"><anchor id="ch0146s0000a0103"/><link linkend="ch0146s0000a0098"><emphasis role="strong">FIGURE 16</emphasis></link></phrase> <emphasis>Basidiobolus ranarum.</emphasis> (A) Ten-day-old, wrinkled colony on PDA medium; (B) uninucleate hyphal elements; (C) young zygospores.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0146f16.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
    </sect1>
    <sect1 id="ch0146s0031">
      <title>Evaluation, Interpretation, and Reporting of Results</title>
      <anchor id="ch0146s0031a0001"/>
      <anchor id="ch0146s0000a0104"/>
      <para id="ch0146s0000p0113">In areas of endemicity, final diagnosis is based on the combination of direct examination showing broad, thin-walled hyphae with a Splendore-Hoeppli phenomenon without necrosis or invasion of blood vessels. In cases with positive cultures, results of antifungal susceptibility testing do not currently influence the therapeutic decision.</para>
      <sect2 id="ch0146s0031s0001">
        <title>REFERENCES</title>
        <anchor id="ch0146s0031a0002"/>
        <anchor id="ch0146s0000a0105"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0146s0000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, et al.</emphasis> 2007. A higher-level phylogenetic classification of the Fungi. <citetitle><emphasis>Mycol Res</emphasis></citetitle> <emphasis role="strong">111:</emphasis>509–547.</para>
          </listitem>
          <listitem id="ch0146s0000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Spatafora JW, Chang Y, Benny GL, Lazarus K, Smith ME, Berbee ML, Bonito G, Corradi N, Grigoriev I, Gryganskyi A, James TY, O’Donnell K, Roberson RW, Taylor TN, Uehling J, Vilgalys R, White MM, Stajich JE.</emphasis> 2016. A phylum-level phylogenetic classification of zygomycete fungi based on genome-scale data. <citetitle><emphasis>Mycologia</emphasis></citetitle> <emphasis role="strong">108:</emphasis>1028–1046.</para>
          </listitem>
          <listitem id="ch0146s0000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Naranjo-Ortiz MA, Gabaldón T.</emphasis> 2019. Fungal evolution: diversity, taxonomy and phylogeny of the <citetitle><emphasis>Fungi. Biol Rev Camb Philos Soc</emphasis></citetitle> <emphasis role="strong">94:</emphasis>2101–2137.</para>
          </listitem>
          <listitem id="ch0146s0000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">O’Donnell K, Lutzoni F, Ward TJ, Benny GL.</emphasis> 2001. Evolutionary relationships among mucoralean fungi (Zygomycota): evidence for family polyphyly on a large scale. <citetitle><emphasis>Mycologia</emphasis></citetitle> <emphasis role="strong">93:</emphasis>286–296.</para>
          </listitem>
          <listitem id="ch0146s0000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Voigt K, Cigelnik E, O’donnell K.</emphasis> 1999. Phylogeny and PCR identification of clinically important Zygomycetes based on nuclear ribosomal-DNA sequence data. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>3957–3964.</para>
          </listitem>
          <listitem id="ch0146s0000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Voigt K, Wöstemeyer J.</emphasis> 2001. Phylogeny and origin of 82 zygomycetes from all 54 genera of the Mucorales and Mortierellales based on combined analysis of actin and translation elongation factor EF-1alpha genes. <citetitle><emphasis>Gene</emphasis></citetitle> <emphasis role="strong">270:</emphasis>113–120.</para>
          </listitem>
          <listitem id="ch0146s0000li0007" role="bibliographyEntry">
            <anchor id="ch0146s0000a0106"/>
            <para>7.<emphasis role="strong">Hoffmann K, Pawłowska J, Walther G, Wrzosek M, de Hoog GS, Benny GL, Kirk PM, Voigt K.</emphasis> 2013. The family structure of the Mucorales: a synoptic revision based on comprehensive multigene-genealogies. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">30:</emphasis>57–76.</para>
          </listitem>
          <listitem id="ch0146s0000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Garcia-Hermoso D, Hoinard D, Gantier JC, Grenouillet F, Dromer F, Dannaoui E.</emphasis> 2009. Molecular and phenotypic evaluation of <citetitle><emphasis>Lichtheimia corymbifera</emphasis></citetitle> (formerly <citetitle><emphasis>Absidia corymbifera</emphasis></citetitle>) complex isolates associated with human mucormycosis: rehabilitation of <citetitle><emphasis>L. ramosa. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3862–3870.</para>
          </listitem>
          <listitem id="ch0146s0000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Hoffmann K, Discher S, Voigt K.</emphasis> 2007. Revision of the genus <citetitle><emphasis>Absidia</emphasis></citetitle> (Mucorales, Zygomycetes) based on physiological, phylogenetic, and morphological characters; thermotolerant <citetitle><emphasis>Absidia</emphasis></citetitle> spp. form a coherent group, <citetitle><emphasis>Mycocladiaceae fam. nov. Mycol Res</emphasis></citetitle> <emphasis role="strong">111:</emphasis>1169–1183.</para>
          </listitem>
          <listitem id="ch0146s0000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, Rodriguez-Tudela JL, Voigt K, Bibashi E, Walther G.</emphasis> 2010. Species recognition and clinical relevance of the zygomycetous genus <citetitle><emphasis>Lichtheimia</emphasis></citetitle> (syn. <citetitle><emphasis>Absidia</emphasis></citetitle> pro parte, Mycocladus). <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2154–2170.</para>
          </listitem>
          <listitem id="ch0146s0000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Alvarez E, Stchigel AM, Cano J, Sutton DA, Fothergill AW, Chander J, Salas V, Rinaldi MG, Guarro J.</emphasis> 2010. Molecular phylogenetic diversity of the emerging mucoralean fungus <citetitle><emphasis>Apophysomyces</emphasis></citetitle>: proposal of three new species. <citetitle><emphasis>Rev Iberoam Micol</emphasis></citetitle> <emphasis role="strong">27:</emphasis>80–89.</para>
          </listitem>
          <listitem id="ch0146s0000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Alvarez E, Cano J, Stchigel AM, Sutton DA, Fothergill AW, Salas V, Rinaldi MG, Guarro J.</emphasis> 2011. Two new species of <citetitle><emphasis>Mucor</emphasis></citetitle> from clinical samples. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>62–72.</para>
          </listitem>
          <listitem id="ch0146s0000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Ma LJ, Ibrahim AS, Skory C, Grabherr MG, Burger G, Butler M, Elias M, Idnurm A, Lang BF, Sone T, Abe A, Calvo SE, Corrochano LM, Engels R, Fu J, Hansberg W, Kim JM, Kodira CD, Koehrsen MJ, Liu B, Miranda-Saavedra D, O’Leary S, Ortiz-Castellanos L, Poulter R, Rodriguez-Romero J, Ruiz-Herrera J, Shen YQ, Zeng Q, Galagan J, Birren BW, Cuomo CA, Wickes BL.</emphasis> 2009. Genomic analysis of the basal lineage fungus <citetitle><emphasis>Rhizopus oryzae</emphasis></citetitle> reveals a whole-genome duplication. <citetitle><emphasis>PLoS Genet</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e1000549.</para>
          </listitem>
          <listitem id="ch0146s0000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Humber RA.</emphasis> 2012. Entomophthoromycota: a new phylum and reclassification of entomophthoroid fungi. <citetitle><emphasis>Mycotaxon</emphasis></citetitle> <emphasis role="strong">120:</emphasis>477–492.</para>
          </listitem>
          <listitem id="ch0146s0000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Gryganskyi AP, Humber RA, Smith ME, Miadlikowska J, Wu S, Voigt K, Walther G, Anishchenko IM, Vilgalys R.</emphasis> 2012. Molecular phylogeny of the Entomophthoromycota. <citetitle><emphasis>Mol Phylogenet Evol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>682–694.</para>
          </listitem>
          <listitem id="ch0146s0000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">de Hoog GS, Guarro J, Gené J, Figueras MJ.</emphasis> 2011. <citetitle><emphasis>Atlas of Clinical Fungi CD-ROM</emphasis></citetitle>, <citetitle><emphasis>3.1.</emphasis></citetitle> Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.</para>
          </listitem>
          <listitem id="ch0146s0000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Gryganskyi AP, Humber RA, Smith ME, Hodge K, Huang B, Voigt K, Vilgalys R.</emphasis> 2013. Phylogenetic lineages in Entomophthoromycota. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">30:</emphasis>94–105.</para>
          </listitem>
          <listitem id="ch0146s0000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Ribes JA, Vanover-Sams CL, Baker DJ.</emphasis> 2000. Zygomycetes in human disease. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">13:</emphasis>236–301.</para>
          </listitem>
          <listitem id="ch0146s0000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O, French Mycosis Study Group.</emphasis> 2012. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">54</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S35–S43.</para>
          </listitem>
          <listitem id="ch0146s0000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, Etienne K, Deak E, Derado G, Shieh WJ, Drew C, Zaki S, Sugerman D, Gade L, Thompson EH, Sutton DA, Engelthaler DM, Schupp JM, Brandt ME, Harris JR, Lockhart SR, Turabelidze G, Park BJ.</emphasis> 2012. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">367:</emphasis>2214–2225.</para>
          </listitem>
          <listitem id="ch0146s0000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR, Ganesan A, Li P, Bradley W, Gaskins LJ, Seillier-Moiseiwitsch F, Murray CK, Millar EV, Keenan B, Paolino K, Fleming M, Hospenthal DR, Wortmann GW, Landrum ML, Kortepeter MG, Tribble DR, Infectious Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group.</emphasis> 2012. Invasive mold infections following combat-related injuries. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1441–1449.</para>
          </listitem>
          <listitem id="ch0146s0000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Kwon-Chung K, Bennett J.</emphasis> 1982. <citetitle><emphasis>Medical Mycology.</emphasis></citetitle> Lea &amp; Febiger, Philadelphia, PA.</para>
          </listitem>
          <listitem id="ch0146s0000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O.</emphasis> 2012. Healthcare-associated mucormycosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">54</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S44–S54.</para>
          </listitem>
          <listitem id="ch0146s0000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Guarro J, Chander J, Alvarez E, Stchigel AM, Robin K, Dalal U, Rani H, Punia RS, Cano JF.</emphasis> 2011. <citetitle><emphasis>Apophysomyces variabilis</emphasis></citetitle> infections in humans. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>134–135.</para>
          </listitem>
          <listitem id="ch0146s0000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Legrand M, Gits-Muselli M, Boutin L, Garcia-Hermoso D, Maurel V, Soussi S, Benyamina M, Ferry A, Chaussard M, Hamane S, Denis B, Touratier S, Guigue N, Fréalle E, Jeanne M, Shaal JV, Soler C, Mimoun M, Chaouat M, Lafaurie M, Mebazaa A, Bretagne S, Alanio A.</emphasis> 2016. Detection of circulating Mucorales DNA in critically ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>1312–1317.</para>
          </listitem>
          <listitem id="ch0146s0000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Duffy J, Harris J, Gade L, Sehulster L, Newhouse E, O’Connell H, Noble-Wang J, Rao C, Balajee SA, Chiller T.</emphasis> 2014. Mucormycosis outbreak associated with hospital linens. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">33:</emphasis>472–476.</para>
          </listitem>
          <listitem id="ch0146s0000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Lee SC, Billmyre RB, Li A, Carson S, Sykes SM, Huh EY, Mieczkowski P, Ko DC, Cuomo CA, Heitman J.</emphasis> 2014. Analysis of a food-borne fungal pathogen outbreak: virulence and genome of a <citetitle><emphasis>Mucor circinelloides</emphasis></citetitle> isolate from yogurt. <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e01390-14.</para>
          </listitem>
          <listitem id="ch0146s0000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G, European Confederation of Medical Mycology Working Group on Zygomycosis.</emphasis> 2011. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1859–1867.</para>
          </listitem>
          <listitem id="ch0146s0000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Bretagne S, Sitbon K, Desnos-Ollivier M, Garcia-Hermoso D, Letscher-Bru V, Cassaing S, Millon L, Morio F, Gangneux JP, Hasseine L, Favennec L, Cateau E, Bailly E, Moniot M, Bonhomme J, Desbois-Nogard N, Chouaki T, Paugam A, Bouteille B, Pihet M, Dalle F, Eloy O, Sasso M, Demar M, Mariani-Kurkdjian P, Robert V, Lortholary O, Dromer F,</emphasis> French Mycoses Study Group. 2022. Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF Network (2012 to 2018). <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">13:</emphasis>e00920-22.</para>
          </listitem>
          <listitem id="ch0146s0000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Chakrabarti A, Singh R.</emphasis> 2014. Mucormycosis in India: unique features. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">57</emphasis>(Suppl 3)<emphasis role="strong">:</emphasis>85–90.</para>
          </listitem>
          <listitem id="ch0146s0000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Chayakulkeeree M, Ghannoum MA, Perfect JR.</emphasis> 2006. Zygomycosis: the re-emerging fungal infection. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">25:</emphasis>215–229.</para>
          </listitem>
          <listitem id="ch0146s0000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II.</emphasis> 2005. Zygomycosis in a tertiary-care cancer center in the era of <citetitle><emphasis>Aspergillus</emphasis></citetitle>-active antifungal therapy: a case-control observational study of 27 recent cases. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">191:</emphasis>1350–1360.</para>
          </listitem>
          <listitem id="ch0146s0000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Marty FM, Cosimi LA, Baden LR.</emphasis> 2004. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">350:</emphasis>950–952.</para>
          </listitem>
          <listitem id="ch0146s0000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Prabhu RM, Patel R.</emphasis> 2004. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">10</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>31–47.</para>
          </listitem>
          <listitem id="ch0146s0000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Marr KA, Carter RA, Crippa F, Wald A, Corey L.</emphasis> 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>909–917.</para>
          </listitem>
          <listitem id="ch0146s0000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O.</emphasis> 2009. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>1395–1401.</para>
          </listitem>
          <listitem id="ch0146s0000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Bitar D, Morizot G, Van Cauteren D, Dannaoui E, Lanternier F, Lortholary O, Dromer F.</emphasis> 2012. Estimating the burden of mucormycosis infections in France (2005-2007) through a capture-recapture method on laboratory and administrative data. <citetitle><emphasis>Rev Epidemiol Sante Publique</emphasis></citetitle> <emphasis role="strong">60:</emphasis>383–387.</para>
          </listitem>
          <listitem id="ch0146s0000li0038" role="bibliographyEntry">
            <anchor id="ch0146s0000a0107"/>
            <para>38.<emphasis role="strong">Bitar D, Lortholary O, Dromer F, Coignard B, Che D.</emphasis> 2013. Invasive fungal infections in hospital discharge data, metropolitan France, 2001–2010: incidence, lethality and trends. <citetitle><emphasis>Bull Epidemiol Hebd (Paris)</emphasis></citetitle> <emphasis role="strong">2013:</emphasis>109–114.</para>
          </listitem>
          <listitem id="ch0146s0000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL.</emphasis> 1998. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1138–1147.</para>
          </listitem>
          <listitem id="ch0146s0000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea I, Bouza E, MYCOMED Zygomycosis Study Group.</emphasis> 2007. Impact of zygomycosis on microbiology workload: a survey study in Spain. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2051–2053.</para>
          </listitem>
          <listitem id="ch0146s0000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F.</emphasis> 2014. Population-based analysis of invasive fungal infections, France, 2001-2010. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1149–1155.</para>
          </listitem>
          <listitem id="ch0146s0000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ.</emphasis> 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>634–653.</para>
          </listitem>
          <listitem id="ch0146s0000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Lanternier F, Lortholary O.</emphasis> 2009. Zygomycosis and diabetes mellitus. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">15</emphasis>(Suppl 5)<emphasis role="strong">:</emphasis>21–25.</para>
          </listitem>
          <listitem id="ch0146s0000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, Rao P, Panda N, Verma SC, Sakhuja V.</emphasis> 2006. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>335–342.</para>
          </listitem>
          <listitem id="ch0146s0000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Prasad PA, Chu JH, Walsh TJ.</emphasis> 2007. Zygomycosis in children: a systematic review and analysis of reported cases. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">26:</emphasis>723–727.</para>
          </listitem>
          <listitem id="ch0146s0000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Muñoz P, Patel R, Fortun J, Martin-Davila P, Philippe B, Philit F, Tabah A, Terzi N, Chatelet V, Kusne S, Clark N, Blumberg E, Julia MB, Humar A, Houston S, Lass-Flörl C, Johnson L, Dubberke ER, Barron MA, Lortholary O.</emphasis> 2009. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">200:</emphasis>1002–1011.</para>
          </listitem>
          <listitem id="ch0146s0000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Eker C, Tarkan O, Surmelioglu O, Dagkiran M, Tanrisever I, Yucel Karakaya SP, Ulas B, Onan E, Uguz AH, Ozdemir S.</emphasis> 2022. Alternating pattern of rhino-orbital-cerebral mucormycosis with COVID-19 in diabetic patients. <citetitle><emphasis>Eur Arch Otorhinolaryngol</emphasis></citetitle> <emphasis role="strong">280:</emphasis>219–226.</para>
          </listitem>
          <listitem id="ch0146s0000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Pandit AK, Tangri P, Misra S, Srivastava MVP, Bhatnagar S, Thakar A, Sikka K, Panda S, Vishnu VY, Singh RK, Das A, Radhakrishnan DM, Srivastava AK, Subramaniam R, Trikha A, Agarwal A, Rajan R, Upadhyay V, Parikipandla S, Singh A, Kairo A.</emphasis> 2022. Mucormycosis in COVID-19 patients: a case-control study. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1209.</para>
          </listitem>
          <listitem id="ch0146s0000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Patel AK, Bakshi H, Shah K, Patel S, Patel T, Patel K, Patel KK.</emphasis> 2022. Risk factors for COVID-19 associated mucormycosis in India: a case control study. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>myac044.</para>
          </listitem>
          <listitem id="ch0146s0000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Balushi AA, Ajmi AA, Sinani QA, Menon V, Berieki ZA, Shezawi AA, Azri SA, Rashdi AA, Jardani AA, Baluki TA, Ghaithi SA, Reesi AA, Al-Za’abi AT, Al’ Balushi MA, Maqbali TA.</emphasis> 2022. COVID-19-associated mucormycosis: an opportunistic fungal infection. a case series and review. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">121:</emphasis>203–210.</para>
          </listitem>
          <listitem id="ch0146s0000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Danion F, Letscher-Bru V, Guitard J, Sitbon K, Dellière S, Angoulvant A, Desoubeaux G, Botterel F, Bellanger AP, Gargala G, Uhel F, Bougnoux ME, Gerber V, Michel J, Cornu M, Bretagne S, Lanternier F, COVID-Mucor study group.</emphasis> 2021. Coronavirus disease 2019-associated mucormycosis in France: a rare but deadly complication. Open Forum Infect Dis <emphasis role="strong">9:</emphasis>ofab566.</para>
          </listitem>
          <listitem id="ch0146s0000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP.</emphasis> 2005. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>60–66.</para>
          </listitem>
          <listitem id="ch0146s0000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A.</emphasis> 2006. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. <citetitle><emphasis>Haematologica</emphasis></citetitle> <emphasis role="strong">91:</emphasis>1068–1075.</para>
          </listitem>
          <listitem id="ch0146s0000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, Molteni A, Morra E.</emphasis> 2000. Mucormycosis in hematologic malignancies: an emerging fungal infection. <citetitle><emphasis>Haematologica</emphasis></citetitle> <emphasis role="strong">85:</emphasis>1068–1071.</para>
          </listitem>
          <listitem id="ch0146s0000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Picardi M, Corvatta L, D’Antonio D, Girmenia C, Martino P, Del Favero A, GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) Infection Program.</emphasis> 2004. Mucormycosis in hematologic patients. <citetitle><emphasis>Haematologica</emphasis></citetitle> <emphasis role="strong">89:</emphasis>207–214.</para>
          </listitem>
          <listitem id="ch0146s0000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV.</emphasis> 2000. Zygomycosis in the 1990s in a tertiary-care cancer center. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>851–856.</para>
          </listitem>
          <listitem id="ch0146s0000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG.</emphasis> 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1091–1100.</para>
          </listitem>
          <listitem id="ch0146s0000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K.</emphasis> 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">48:</emphasis>265–273.</para>
          </listitem>
          <listitem id="ch0146s0000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Blin N, Morineau N, Gaillard F, Morin O, Milpied N, Harousseau JL, Moreau P.</emphasis> 2004. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin’s lymphoma. <citetitle><emphasis>Leuk Lymphoma</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2161–2163.</para>
          </listitem>
          <listitem id="ch0146s0000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA.</emphasis> 2004. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>743–746.</para>
          </listitem>
          <listitem id="ch0146s0000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Safdar A, O’Brien S, Kouri IF.</emphasis> 2004. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">34:</emphasis>467–468.</para>
          </listitem>
          <listitem id="ch0146s0000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Girmenia C, Moleti ML, Micozzi A, Iori AP, Barberi W, Foà R, Martino P.</emphasis> 2005. Breakthrough <citetitle><emphasis>Candida krusei</emphasis></citetitle> fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>5395–5396.</para>
          </listitem>
          <listitem id="ch0146s0000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L, French Innovative Leukemia Organization (FILO) CLL group.</emphasis> 2018. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. <citetitle><emphasis>Blood</emphasis></citetitle> <emphasis role="strong">131:</emphasis>1955–1959.</para>
          </listitem>
          <listitem id="ch0146s0000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Pouvaret A, Guery R, Montillet M, Molina TJ, Duréault A, Bougnoux ME, Galliot R, Lanternier F, Delarue R, Lortholary O.</emphasis> 2019. Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">25:</emphasis>771–773.</para>
          </listitem>
          <listitem id="ch0146s0000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM.</emphasis> 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1101–1111.</para>
          </listitem>
          <listitem id="ch0146s0000li0066" role="bibliographyEntry">
            <anchor id="ch0146s0000a0108"/>
            <para>66.<emphasis role="strong">Thatipelli S, Santoiemma P, Echenique IA, Green R, Ison MG, Ladner D, Kanwar YS, Stosor V.</emphasis> 2021. Donor-derived renal allograft mucormycosis in a combined liver and kidney transplantation: case report and review of the literature. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>e13534.</para>
          </listitem>
          <listitem id="ch0146s0000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Garner D, Machin K.</emphasis> 2008. Investigation and management of an outbreak of mucormycosis in a paediatric oncology unit. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">70:</emphasis>53–59.</para>
          </listitem>
          <listitem id="ch0146s0000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Sundermann AJ, Clancy CJ, Pasculle AW, Liu G, Cumbie RB, Driscoll E, Ayres A, Donahue L, Pergam SA, Abbo L, Andes DR, Chandrasekar P, Galdys AL, Hanson KE, Marr KA, Mayer J, Mehta S, Morris MI, Perfect J, Revankar SG, Smith B, Swaminathan S, Thompson GR III, Varghese M, Vazquez J, Whimbey E, Wingard JR, Nguyen MH.</emphasis> 2019. How clean is the linen at my hospital? The Mucorales on Unclean Linen Discovery Study of large United States transplant and cancer centers. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">68:</emphasis>850–853.</para>
          </listitem>
          <listitem id="ch0146s0000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM.</emphasis> 2008. Reversed halo sign in invasive pulmonary fungal infections. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1733–1737.</para>
          </listitem>
          <listitem id="ch0146s0000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, Pagès PB, Roques M, Estivalet L, Martin L, Maitre T, Bastie JN, Dalle F.</emphasis> 2014. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">58:</emphasis>672–678.</para>
          </listitem>
          <listitem id="ch0146s0000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP.</emphasis> 2011. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1144–1155.</para>
          </listitem>
          <listitem id="ch0146s0000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Marchiori E, Pereira ML, Zanetti G.</emphasis> 2018. The Importance of the Reversed Halo Sign in the Diagnosis of Pulmonary Mucormycosis. <citetitle><emphasis>AJR Am J Roentgenol</emphasis></citetitle> <emphasis role="strong">211</emphasis>(<link linkend="ch0146s0000li0002">2</link>)<emphasis role="strong">:</emphasis>W137.</para>
          </listitem>
          <listitem id="ch0146s0000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Sun HY, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Muñoz P, Patel R, Fortun J, Martin-Davila P, Philippe B, Philit F, Tabah A, Terzi N, Chatelet V, Kusne S, Clark N, Blumberg E, Julia MB, Humar A, Houston S, Lass-Florl C, Johnson L, Dubberke ER, Barron MA, Lortholary O, Singh N, Zygomycosis Transplant Study Group.</emphasis> 2009. Pulmonary zygomycosis in solid organ transplant recipients in the current era. <citetitle><emphasis>Am J Transplant</emphasis></citetitle> <emphasis role="strong">9:</emphasis>2166–2171.</para>
          </listitem>
          <listitem id="ch0146s0000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Almaslamani M, Taj-Aldeen SJ, Garcia-Hermoso D, Dannaoui E, Alsoub H, Alkhal A.</emphasis> 2009. An increasing trend of cutaneous zygomycosis caused by <citetitle><emphasis>Mycocladus corymbifer</emphasis></citetitle> (formerly <citetitle><emphasis>Absidia corymbifera</emphasis></citetitle>): report of two cases and review of primary cutaneous <citetitle><emphasis>Mycocladus</emphasis></citetitle> infections. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>532–538.</para>
          </listitem>
          <listitem id="ch0146s0000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Vitrat-Hincky V, Lebeau B, Bozonnet E, Falcon D, Pradel P, Faure O, Aubert A, Piolat C, Grillot R, Pelloux H.</emphasis> 2009. Severe filamentous fungal infections after widespread tissue damage due to traumatic injury: six cases and review of the literature. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>491–500.</para>
          </listitem>
          <listitem id="ch0146s0000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Lelievre L, Garcia-Hermoso D, Abdoul H, Hivelin M, Chouaki T, Toubas D, Mamez AC, Lantieri L, Lortholary O, Lanternier F, and the French Mycosis Study Group.</emphasis> 2014. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">93:</emphasis>395–404.</para>
          </listitem>
          <listitem id="ch0146s0000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D.</emphasis> 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">356:</emphasis>348–359.</para>
          </listitem>
          <listitem id="ch0146s0000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S.</emphasis> 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">356:</emphasis>335–347.</para>
          </listitem>
          <listitem id="ch0146s0000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Axell-House DB, Wurster S, Jiang Y, Kyvernitakis A, Lewis RE, Tarrand JJ, Raad II, Kontoyiannis DP.</emphasis> 2021. Breakthrough mucormycosis developing on Mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">7:</emphasis>217.</para>
          </listitem>
          <listitem id="ch0146s0000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Walsh TJ, Kontoyiannis DP.</emphasis> 2008. Editorial commentary: What is the role of combination therapy in management of zygomycosis? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>372–374.</para>
          </listitem>
          <listitem id="ch0146s0000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R.</emphasis> 2017. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <citetitle><emphasis>Haematologica</emphasis></citetitle> <emphasis role="strong">102:</emphasis>433–444.</para>
          </listitem>
          <listitem id="ch0146s0000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Vironneau P, Kania R, Morizot G, Elie C, Garcia-Hermoso D, Herman P, Lortholary O, Lanternier F, French Mycosis Study Group.</emphasis> 2014. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">20:</emphasis>O336–O339.</para>
          </listitem>
          <listitem id="ch0146s0000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Lanternier F, Lortholary O.</emphasis> 2008. Liposomal amphotericin B: what is its role in 2008? <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">14</emphasis>(Suppl 4)<emphasis role="strong">:</emphasis>71–83.</para>
          </listitem>
          <listitem id="ch0146s0000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Björkholm M, Runarsson G, Celsing F, Kalin M, Petrini B, Engervall P.</emphasis> 2001. Liposomal amphotericin B and surgery in the successful treatment of invasive pulmonary mucormycosis in a patient with acute T-lymphoblastic leukemia. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">33:</emphasis>316–319.</para>
          </listitem>
          <listitem id="ch0146s0000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Parkyn T, McNinch AW, Riordan T, Mott M.</emphasis> 2000. Zygomycosis in relapsed acute leukaemia. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">41:</emphasis>265–268.</para>
          </listitem>
          <listitem id="ch0146s0000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Cornely OA, Alastgruey-Izquierdo A, Arenz D, Chen SCA, Dannoui E, Mucormycosis ECMM MSG Global Guideline Writing Group, et al.</emphasis> 2019. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>e405–e421.</para>
          </listitem>
          <listitem id="ch0146s0000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR III, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Rá</emphasis>č<emphasis role="strong">il Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT, VITAL and FungiScope Mucormycosis Investigators.</emphasis> 2016. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>828–837.</para>
          </listitem>
          <listitem id="ch0146s0000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, Herbrecht R, Wolff M, Ribaud P, Lortholary O, French Mycosis Study Group.</emphasis> 2015. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">70:</emphasis>3116–3123.</para>
          </listitem>
          <listitem id="ch0146s0000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Chamilos G, Lewis RE, Kontoyiannis DP.</emphasis> 2008. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>503–509.</para>
          </listitem>
          <listitem id="ch0146s0000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S, European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups.</emphasis> 2012. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">47:</emphasis>846–854.</para>
          </listitem>
          <listitem id="ch0146s0000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Arendrup MC, Bille J, Dannaoui E, Ruhnke M, Heussel CP, Kibbler C.</emphasis> 2012. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1030–1045.</para>
          </listitem>
          <listitem id="ch0146s0000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N.</emphasis> 2000. The role of BAL in the diagnosis of pulmonary mucormycosis. <citetitle><emphasis>Chest</emphasis></citetitle> <emphasis role="strong">117:</emphasis>279–282.</para>
          </listitem>
          <listitem id="ch0146s0000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Nosari A, Anghilieri M, Carrafiello G, Guffanti C, Marbello L, Montillo M, Muti G, Ribera S, Vanzulli A, Nichelatti M, Morra E.</emphasis> 2003. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. <citetitle><emphasis>Haematologica</emphasis></citetitle> <emphasis role="strong">88:</emphasis>1405–1409.</para>
          </listitem>
          <listitem id="ch0146s0000li0094" role="bibliographyEntry">
            <anchor id="ch0146s0000a0109"/>
            <para>94.<emphasis role="strong">Leber AL (ed).</emphasis> 2016. Mycology and antifungal susceptibility testing. <citetitle><emphasis>In</emphasis></citetitle> Leber AL (ed), <citetitle><emphasis>Clinical Microbiology Procedures Handbook, vol 2.</emphasis></citetitle> ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0146s0000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Lass-Flörl C.</emphasis> 2009. Zygomycosis: conventional laboratory diagnosis. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">15</emphasis>(Suppl 5)<emphasis role="strong">:</emphasis>60–65.</para>
          </listitem>
          <listitem id="ch0146s0000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Frater JL, Hall GS, Procop GW.</emphasis> 2001. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. <citetitle><emphasis>Arch Pathol Lab Med</emphasis></citetitle> <emphasis role="strong">125:</emphasis>375–378.</para>
          </listitem>
          <listitem id="ch0146s0000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Guarner J, Brandt ME.</emphasis> 2011. Histopathologic diagnosis of fungal infections in the 21st century. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">24:</emphasis>247–280.</para>
          </listitem>
          <listitem id="ch0146s0000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Cornu M, Sendid B, Mery A, François N, Mikulska M, Letscher-Bru V, De Carolis E, Damonti L, Titecat M, Bochud P-Y, Alanio A, Sanguinetti M, Viscoli C, Herbrecht R, Guerardel Y, Poulain D.</emphasis> 2019. Evaluation of mass spectrometry-based detection of panfungal serum disaccharide for diagnosis of invasive fungal infections: results from a collaborative study involving xix European clinical centers. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e01867-18.</para>
          </listitem>
          <listitem id="ch0146s0000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Burnham-Marusich AR, Hubbard B, Kvam AJ, Gates-Hollingsworth M, Green HR, Soukup E, Limper AH, Kozel TR.</emphasis> 2018. Conservation of mannan synthesis in fungi ofthe Zygomycota and Ascomycota reveals abroad diagnostic target. <citetitle><emphasis>mSphere</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e00094-18.</para>
          </listitem>
          <listitem id="ch0146s0000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S.</emphasis> 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2587–2590.</para>
          </listitem>
          <listitem id="ch0146s0000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP.</emphasis> 2012. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">54</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S55–S60.</para>
          </listitem>
          <listitem id="ch0146s0000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Buitrago MJ, Aguado JM, Ballen A, Bernal-Martinez L, Prieto M, Garcia-Reyne A, Garcia-Rodriguez J, Rodriguez-Tudela JL, Cuenca-Estrella M.</emphasis> 2013. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">19:</emphasis>E271–E277.</para>
          </listitem>
          <listitem id="ch0146s0000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Cabaret O, Toussain G, Abermil N, Alsamad IA, Botterel F, Costa JM, Papon JF, Bretagne S.</emphasis> 2011. Degradation of fungal DNA in formalin-fixed paraffin-embedded sinus fungal balls hampers reliable sequence-based identification of fungi. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>329–332.</para>
          </listitem>
          <listitem id="ch0146s0000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Schwarz P, Bretagne S, Gantier JC, Garcia-Hermoso D, Lortholary O, Dromer F, Dannaoui E.</emphasis> 2006. Molecular identification of zygomycetes from culture and experimentally infected tissues. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>340–349.</para>
          </listitem>
          <listitem id="ch0146s0000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Bialek R, Konrad F, Kern J, Aepinus C, Cecenas L, Gonzalez GM, Just-Nübling G, Willinger B, Presterl E, Lass-Flörl C, Rickerts V.</emphasis> 2005. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>1180–1184.</para>
          </listitem>
          <listitem id="ch0146s0000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Rickerts V, Just-Nübling G, Konrad F, Kern J, Lambrecht E, Böhme A, Jacobi V, Bialek R.</emphasis> 2006. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">25:</emphasis>8–13.</para>
          </listitem>
          <listitem id="ch0146s0000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Rickerts V, Mousset S, Lambrecht E, Tintelnot K, Schwerdtfeger R, Presterl E, Jacobi V, Just-Nübling G, Bialek R.</emphasis> 2007. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1078–1083.</para>
          </listitem>
          <listitem id="ch0146s0000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL.</emphasis> 2008. Real-time PCR method for detection of zygomycetes. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2353–2358.</para>
          </listitem>
          <listitem id="ch0146s0000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Salehi E, Hedayati MT, Zoll J, Rafati H, Ghasemi M, Doroudinia A, Abastabar M, Tolooe A, Snelders E, van der Lee HA, Rijs AJ, Verweij PE, Seyedmousavi S, Melchers WJ.</emphasis> 2016. Discrimination of aspergillosis, mucormycosis, fusariosis and scedosporiosis in formalin-fixed paraffin-embedded tissue specimens using multiple real-time quantitative PCR assays. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2798–2803.</para>
          </listitem>
          <listitem id="ch0146s0000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Alanio A, Garcia-Hermoso D, Mercier-Delarue S, Lanternier F, Gits-Muselli M, Menotti J, Denis B, Bergeron A, Legrand M, Lortholary O, Bretagne S, French Mycosis Study Group.</emphasis> 2015. Molecular identification of Mucorales in human tissues: contribution of PCR electrospray-ionization mass spectrometry. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">21:</emphasis>594.e1–594.e5.</para>
          </listitem>
          <listitem id="ch0146s0000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Hayden RT, Qian X, Procop GW, Roberts GD, Lloyd RV.</emphasis> 2002. In situ hybridization for the identification of filamentous fungi in tissue section. <citetitle><emphasis>Diagn Mol Pathol</emphasis></citetitle> <emphasis role="strong">11:</emphasis>119–126.</para>
          </listitem>
          <listitem id="ch0146s0000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Rickerts V, Khot PD, Myerson D, Ko DL, Lambrecht E, Fredricks DN.</emphasis> 2011. Comparison of quantitative real time PCR with sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">11:</emphasis>202.</para>
          </listitem>
          <listitem id="ch0146s0000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S, Daguindau E, Scherer E, Bellanger AP, Leroy J, Grenouillet F.</emphasis> 2013. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e95–e101.</para>
          </listitem>
          <listitem id="ch0146s0000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Millon L, Herbrecht R, Morio F, Alanio A, Letscher-Bru V, Cassaing S, Chouaki T, Kauffmann-LaCroix C, Poirier P, Toubas D, Augereau O, Rocchi S, Garcia-Hermoso D, Bretagne S, French Mycosis Study Group.</emphasis> 2016. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>810.e1–810.e8.</para>
          </listitem>
          <listitem id="ch0146s0000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Millon L, Caillot D, Berceanu A, Bretagne S, Lanternier F, Morio F, Letscher-Bru V, Dalle F, Denis B, Alanio A, Boutoille D, Bougnoux M-E, Botterel F, Chouaki T, Charbonnier A, Ader F, Dupont D, Bellanger A-P, Rocchi S, Scherer E, Gbaguidi-Haore H, Herbrecht R.</emphasis> 2022. Evaluation of serum Mucorales polymerase chain reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR Prospective Trial. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>777–785.</para>
          </listitem>
          <listitem id="ch0146s0000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Springer J, Goldenberger D, Schmidt F, Weisser M, Wehrle-Wieland E, Einsele H, Frei R, Löffler J.</emphasis> 2016. Development and application of two independent real-time PCR assays to detect clinically relevant Mucorales species. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>227–234.</para>
          </listitem>
          <listitem id="ch0146s0000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Springer J, Lackner M, Ensinger C, Risslegger B, Morton CO, Nachbaur D, Lass-Flörl C, Einsele H, Heinz WJ, Loeffler J.</emphasis> 2016. Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>1414–1421.</para>
          </listitem>
          <listitem id="ch0146s0000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Springer J, White PL, Kessel J, Wieters I, Teschner D, Korczynski D, Liebregts T, Cornely OA, Schwartz S, Elgeti T, Meintker L, Krause SW, Posso RB, Heinz WJ, Fuhrmann S, Vehreschild JJ, Einsele H, Rickerts V, Loeffler J.</emphasis> 2018. A comparison of Aspergillus and Mucorales PCR testing of different bronchoalveolar lavage fluid fractions from patients with suspected invasive pulmonary fungal disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01655-17.</para>
          </listitem>
          <listitem id="ch0146s0000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Mercier T, Reynders M, Beuselinck K, Guldentops E, Maertens J, Lagrou K.</emphasis> 2019. Serial detection of circulating Mucorales DNA in invasive mucormycosis: a retrospective multicenter evaluation. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">5:</emphasis>113.</para>
          </listitem>
          <listitem id="ch0146s0000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Guegan H, Iriart X, Bougnoux M-E, Berry A, Robert-Gangneux F, Gangneux J-P.</emphasis> 2020. Evaluation of MucorGenius<superscript>®</superscript> Mucorales PCR assay for the diagnosis of pulmonary mucormycosis. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">81:</emphasis>311–317.</para>
          </listitem>
          <listitem id="ch0146s0000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Schwarz P, Lortholary O, Dromer F, Dannaoui E.</emphasis> 2007. Carbon assimilation profiles as a tool for identification of zygomycetes. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1433–1439.</para>
          </listitem>
          <listitem id="ch0146s0000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Etienne KA, Gillece J, Hilsabeck R, Schupp JM, Colman R, Lockhart SR, Gade L, Thompson EH, Sutton DA, Neblett-Fanfair R, Park BJ, Turabelidze G, Keim P, Brandt ME, Deak E, Engelthaler DM.</emphasis> 2012. Whole genome sequence typing to investigate the <citetitle><emphasis>Apophysomyces</emphasis></citetitle> outbreak following a tornado in Joplin, Missouri, 2011. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e49989.</para>
          </listitem>
          <listitem id="ch0146s0000li0123" role="bibliographyEntry">
            <anchor id="ch0146s0000a0110"/>
            <para>123.<emphasis role="strong">Gomes MZ, Lewis RE, Kontoyiannis DP.</emphasis> 2011. Mucormycosis caused by unusual mucormycetes, non-<citetitle><emphasis>Rhizopus</emphasis></citetitle>, -<citetitle><emphasis>Mucor</emphasis></citetitle>, and -<citetitle><emphasis>Lichtheimia</emphasis></citetitle> species. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">24:</emphasis>411–445.</para>
          </listitem>
          <listitem id="ch0146s0000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Chakrabarti A, Singh R.</emphasis> 2011. The emerging epidemiology of mould infections in developing countries. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>521–526.</para>
          </listitem>
          <listitem id="ch0146s0000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Padhye AA, Ajello L.</emphasis> 1988. Simple method of inducing sporulation by <citetitle><emphasis>Apophysomyces elegans</emphasis></citetitle> and <citetitle><emphasis>Saksenaea vasiformis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">26:</emphasis>1861–1863.</para>
          </listitem>
          <listitem id="ch0146s0000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Gams W, Hoekstra E, Aptroot A.</emphasis> 1998. <citetitle><emphasis>CBS Course of Mycology.</emphasis></citetitle> Centraalbureau voor Schimmelcultures, Baarn, The Netherlands.</para>
          </listitem>
          <listitem id="ch0146s0000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Ellis D, Davis S, Alexiou H, Handke R, Bartley R.</emphasis> 2007. <citetitle><emphasis>Descriptions of Medical Fungi</emphasis></citetitle>, 2nd ed. Mycology Unit, Women’s and Children’s Hospital, Adelaide, Australia.</para>
          </listitem>
          <listitem id="ch0146s0000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Hoffmann K, Walther G, Voight K.</emphasis> 2009. <citetitle><emphasis>Mycocladus</emphasis></citetitle> vs. <citetitle><emphasis>Lichtheimia</emphasis></citetitle>: a correction (Lichtheimiaceae fam. nov., Mucorales, Mucoromycotina). <citetitle><emphasis>Mycol Res</emphasis></citetitle> <emphasis role="strong">113:</emphasis>277–278.</para>
          </listitem>
          <listitem id="ch0146s0000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">St-Germain G, Summerbell R.</emphasis> 1996. <citetitle><emphasis>Identifying Filamentous Fungi. A Clinical Laboratory Handbook.</emphasis></citetitle> Star Publishing Company, Belmont, CA.</para>
          </listitem>
          <listitem id="ch0146s0000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Lu XL, Najafzadeh MJ, Dolatabadi S, Ran YP, Gerrits van den Ende AH, Shen YN, Li CY, Xi LY, Hao F, Zhang QQ, Li RY, Hu ZM, Lu GX, Wang JJ, Drogari-Apiranthitou M, Klaassen C, Meis JF, Hagen F, Liu WD, de Hoog GS.</emphasis> 2013. Taxonomy and epidemiology of <citetitle><emphasis>Mucor irregularis</emphasis></citetitle>, agent of chronic cutaneous mucormycosis. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">30:</emphasis>48–56.</para>
          </listitem>
          <listitem id="ch0146s0000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Wagner L, Stielow JB, de Hoog GS, Bensch K, Schwartze VU, Voigt K, Alastruey-Izquierdo A, Kurzai O, Walther G.</emphasis> 2020. A new species concept for the clinically relevant <citetitle><emphasis>Mucor circinelloides</emphasis></citetitle> complex. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">44:</emphasis>67–97.</para>
          </listitem>
          <listitem id="ch0146s0000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Schipper MAA.</emphasis> 1976. On <citetitle><emphasis>Mucor circinelloides</emphasis></citetitle>, <citetitle><emphasis>Mucor racemosus</emphasis></citetitle> and related species. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>1–40.</para>
          </listitem>
          <listitem id="ch0146s0000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Karimi K, Arzanlou M, Ahari AB, Ghazi M.</emphasis> 2015. Phenotypic and molecular characterization of the causal agent of chafer beetle mortality in the wheat fields of the Kurdistan province, Iran. <citetitle><emphasis>J Plant Prot Res</emphasis></citetitle> <emphasis role="strong">55:</emphasis>227–234.</para>
          </listitem>
          <listitem id="ch0146s0000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Tully CC, Romanelli AM, Sutton DA, Wickes BL, Hospenthal DR.</emphasis> 2009. Fatal <citetitle><emphasis>Actinomucor elegans</emphasis></citetitle> var. kuwaitiensis infection following combat trauma. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3394–3399.</para>
          </listitem>
          <listitem id="ch0146s0000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Mahmud A, Lee R, Munfus-McCray D, Kwiatkowski N, Subramanian A, Neofytos D, Carroll K, Zhang SX.</emphasis> 2012. <citetitle><emphasis>Actinomucor elegans</emphasis></citetitle> as an emerging cause of mucormycosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1092–1095.</para>
          </listitem>
          <listitem id="ch0146s0000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Dorin J, D’Aveni M, Debourgogne A, Cuenin M, Guillaso M, Rivier A, Gallet P, Lecoanet G, Machouart M.</emphasis> 2017. Update on <citetitle><emphasis>Actinomucor elegans</emphasis></citetitle>, a mucormycete infrequently detected in human specimens: how combined microbiological tools contribute efficiently to a more accurate medical care. <citetitle><emphasis>Int J Med Microbiol</emphasis></citetitle> <emphasis role="strong">307:</emphasis>435–442.</para>
          </listitem>
          <listitem id="ch0146s0000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Davel G, Featherston P, Fernández A, Abrantes R, Canteros C, Rodero L, Sztern C, Perrotta D.</emphasis> 2001. Maxillary sinusitis caused by <citetitle><emphasis>Actinomucor elegans. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>740–742.</para>
          </listitem>
          <listitem id="ch0146s0000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Khan ZU, Ahmad S, Mokaddas E, Chandy R, Cano J, Guarro J.</emphasis> 2008. <citetitle><emphasis>Actinomucor elegans</emphasis></citetitle> var. kuwaitiensis isolated from the wound of a diabetic patient. <citetitle><emphasis>Antonie van Leeuwenhoek</emphasis></citetitle> <emphasis role="strong">94:</emphasis>343–352.</para>
          </listitem>
          <listitem id="ch0146s0000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Hesseltine CW.</emphasis> 1991. Zygomycetes in food fermentations. <citetitle><emphasis>Mycologist</emphasis></citetitle> <emphasis role="strong">5:</emphasis>162–169.</para>
          </listitem>
          <listitem id="ch0146s0000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Han BZ, Kuijpers AFA, Thanh NV, Nout MJR.</emphasis> 2004. Mucoraceous moulds involved in the commercial fermentation of Sufu Pehtze. <citetitle><emphasis>Antonie van Leeuwenhoek</emphasis></citetitle> <emphasis role="strong">85:</emphasis>253–257.</para>
          </listitem>
          <listitem id="ch0146s0000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Bonifaz A, Stchigel AM, Guarro J, Guevara E, Pintos L, Sanchis M, Cano-Lira JF.</emphasis> 2014. Primary cutaneous mucormycosis produced by the new species <citetitle><emphasis>Apophysomyces mexicanus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>4428–4431.</para>
          </listitem>
          <listitem id="ch0146s0000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Alvarez E, Garcia-Hermoso D, Sutton DA, Cano JF, Stchigel AM, Hoinard D, Fothergill AW, Rinaldi MG, Dromer F, Guarro J.</emphasis> 2010. Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>4410–4416.</para>
          </listitem>
          <listitem id="ch0146s0000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Crous PW, Wingfield MJ, Burgess TI, Hardy GE, Crane C, et al.</emphasis> 2016. Fungal Planet description sheets: 469-557. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">37:</emphasis>218–403.</para>
          </listitem>
          <listitem id="ch0146s0000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Crous PW, Wingfield MJ, Burgess TI, Hardy GE, Barber PA, et al.</emphasis> 2017. Fungal Planet description sheets: 558-624. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">38:</emphasis>240–384.</para>
          </listitem>
          <listitem id="ch0146s0000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Schipper MAA.</emphasis> 1984. A revision of the genus <citetitle><emphasis>Rhizopus</emphasis></citetitle>. I. The <citetitle><emphasis>Rhizopus stolonifer</emphasis></citetitle>-group and <citetitle><emphasis>Rhizopus oryzae. Stud Mycol</emphasis></citetitle> <emphasis role="strong">25:</emphasis>1–19.</para>
          </listitem>
          <listitem id="ch0146s0000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Alvarez E, Sutton DA, Cano J, Fothergill AW, Stchigel A, Rinaldi MG, Guarro J.</emphasis> 2009. Spectrum of zygomycete species identified in clinically significant specimens in the United States. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1650–1656.</para>
          </listitem>
          <listitem id="ch0146s0000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Schipper MAA, Stalpers JA.</emphasis> 1984. A revision of the genus <citetitle><emphasis>Rhizopus</emphasis></citetitle>. II. The <citetitle><emphasis>Rhizopus microsporus</emphasis></citetitle> group. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">25:</emphasis>30–34.</para>
          </listitem>
          <listitem id="ch0146s0000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Abe A, Asano K, Sone T.</emphasis> 2010. A molecular phylogeny-based taxonomy of the genus <citetitle><emphasis>Rhizopus. Biosci Biotechnol Biochem</emphasis></citetitle> <emphasis role="strong">74:</emphasis>1325–1331.</para>
          </listitem>
          <listitem id="ch0146s0000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Walther G, Pawłowska J, Alastruey-Izquierdo A, Wrzosek M, Rodriguez-Tudela JL, Dolatabadi S, Chakrabarti A, de Hoog GS.</emphasis> 2013. DNA barcoding in Mucorales: an inventory of biodiversity. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">30:</emphasis>11–47.</para>
          </listitem>
          <listitem id="ch0146s0000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Lemmer K, Losert H, Rickerts V, Just-Nübling G, Sander A, Kerkmann ML, Tintelnot K.</emphasis> 2002. [Molecular biological identification of <citetitle><emphasis>Cunninghamella</emphasis></citetitle> spec]. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">45</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>31–36.</para>
          </listitem>
          <listitem id="ch0146s0000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">García-Rodríguez J, Quiles-Melero I, Humala-Barbier K, Monzon A, Cuenca-Estrella M.</emphasis> 2012. Isolation of <citetitle><emphasis>Cunninghamella blakesleeana</emphasis></citetitle> in an immunodepressed patient. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">55:</emphasis>463–465.</para>
          </listitem>
          <listitem id="ch0146s0000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Holland J.</emphasis> 1997. Emerging zygomycoses of humans: <citetitle><emphasis>Saksenaea vasiformis</emphasis></citetitle> and <citetitle><emphasis>Apophysomyces elegans. Curr Top Med Mycol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>27–34.</para>
          </listitem>
          <listitem id="ch0146s0000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Garcia-Hermoso D, Dannaoui E.</emphasis> 2007. The Zygomycetes, p 159–183. <citetitle><emphasis>In</emphasis></citetitle> Kavanagh K (ed), <citetitle><emphasis>New Insights in Medical Mycology.</emphasis></citetitle> Springer Science, New York, NY.</para>
          </listitem>
          <listitem id="ch0146s0000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, Chen W, Fungal Barcoding Consortium.</emphasis> 2012. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">109:</emphasis>6241–6246.</para>
          </listitem>
          <listitem id="ch0146s0000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, Guarro J, Haase G, Kibbler CC, Meyer W, O’Donnell K, Petti CA, Rodriguez-Tudela JL, Sutton D, Velegraki A, Wickes BL.</emphasis> 2009. Sequence-based identification of <citetitle><emphasis>Aspergillus</emphasis></citetitle>, <citetitle><emphasis>Fusarium</emphasis></citetitle>, and <citetitle><emphasis>Mucorales</emphasis></citetitle> species in the clinical mycology laboratory: where are we and where should we go from here? <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>877–884.</para>
          </listitem>
          <listitem id="ch0146s0000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Abe A, Sone T, Sujaya IN, Saito K, Oda Y, Asano K, Tomita F.</emphasis> 2003. rDNA ITS sequence of <citetitle><emphasis>Rhizopus oryzae</emphasis></citetitle>: its application to classification and identification of lactic acid producers. <citetitle><emphasis>Biosci Biotechnol Biochem</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1725–1731.</para>
          </listitem>
          <listitem id="ch0146s0000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Chakrabarti A, Ghosh A, Prasad GS, David JK, Gupta S, Das A, Sakhuja V, Panda NK, Singh SK, Das S, Chakrabarti T.</emphasis> 2003. Apophysomyces elegans: an emerging zygomycete in India. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>783–788.</para>
          </listitem>
          <listitem id="ch0146s0000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Trabelsi H, Hadrich I, Neji S, Khemakhem N, Hammami B, Makni F, Sellami H, Ayadi A.</emphasis> 2020. Microsatellite analysis of the population structure in <citetitle><emphasis>Rhizopus arrhizus. J Appl Microbiol</emphasis></citetitle> <emphasis role="strong">128:</emphasis>1793–1801.</para>
          </listitem>
          <listitem id="ch0146s0000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Alanio A, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S.</emphasis> 2017. Investigating clinical issues by genotyping of medically important fungi: why and how? <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">30:</emphasis>671–707.</para>
          </listitem>
          <listitem id="ch0146s0000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Garcia-Hermoso D, Criscuolo A, Lee SC, Legrand M, Chaouat M, Denis B, Lafaurie M, Rouveau M, Soler C, Schaal JV, Mimoun M, Mebazaa A, Heitman J, Dromer F, Brisse S, Bretagne S, Alanio A.</emphasis> 2018. Outbreak of invasive wound mucormycosis in a burn unit due to multiple strains of <citetitle><emphasis>Mucor circinelloides</emphasis></citetitle> f. <citetitle><emphasis>circinelloides</emphasis></citetitle> resolved by whole-genome sequencing. <citetitle><emphasis>mBio</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e00573-18.</para>
          </listitem>
          <listitem id="ch0146s0000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Potenza L, Vallerini D, Barozzi P, Riva G, Forghieri F, Zanetti E, Quadrelli C, Candoni A, Maertens J, Rossi G, Morselli M, Codeluppi M, Paolini A, Maccaferri M, Del Giovane C, D’Amico R, Rumpianesi F, Pecorari M, Cavalleri F, Marasca R, Narni F, Luppi M.</emphasis> 2011. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. <citetitle><emphasis>Blood</emphasis></citetitle> <emphasis role="strong">118:</emphasis>5416–5419.</para>
          </listitem>
          <listitem id="ch0146s0000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2017. <citetitle><emphasis>Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi</emphasis></citetitle>, 3rd ed. CLSI standard M38. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0146s0000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing.</emphasis> 2022. EUCAST definitive document E.DEF 9.4-Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. <ulink url="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_9.4_method_for_susceptibility_testing_of_moulds.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_9.4_method_for_susceptibility_testing_of_moulds.pdf</ulink></para>
          </listitem>
          <listitem id="ch0146s0000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Espinel-Ingroff A.</emphasis> 2006. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp., <citetitle><emphasis>Candida</emphasis></citetitle> spp., and <citetitle><emphasis>Cryptococcus neoformans</emphasis></citetitle> with posaconazole and amphotericin B. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3616–3622.</para>
          </listitem>
          <listitem id="ch0146s0000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Dannaoui E, Meis JF, Mouton JW, Verweij PE, Eurofung Network.</emphasis> 2002. In vitro susceptibilities of Zygomycota to polyenes. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>741–744.</para>
          </listitem>
          <listitem id="ch0146s0000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, Eurofung Network.</emphasis> 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>45–52.</para>
          </listitem>
          <listitem id="ch0146s0000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR.</emphasis> 2002. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1581–1582.</para>
          </listitem>
          <listitem id="ch0146s0000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Torres-Narbona M, Guinea J, Martínez-Alarcón J, Peláez T, Bouza E.</emphasis> 2007. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1126–1129.</para>
          </listitem>
          <listitem id="ch0146s0000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M, Voigt K, van de Sande WW, Dolatabadi S, Meis JF, Walther G.</emphasis> 2012. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>66–75.</para>
          </listitem>
          <listitem id="ch0146s0000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Borman AM, Fraser M, Patterson Z, Palmer MD, Johnson EM.</emphasis> 2021. In vitro antifungal drug resistance profiles of clinically relevant members of the <citetitle><emphasis>Mucorales</emphasis></citetitle> (Mucoromycota) especially with the newer triazoles. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">7:</emphasis>271.</para>
          </listitem>
          <listitem id="ch0146s0000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, Fothergill A, Ghannoum M, Gonzalez GM, Guarro J, Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J.</emphasis> 2015. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of <citetitle><emphasis>Mucorales. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1745–1750.</para>
          </listitem>
          <listitem id="ch0146s0000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Dannaoui E, Meis JF, Loebenberg D, Verweij PE.</emphasis> 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3647–3650.</para>
          </listitem>
          <listitem id="ch0146s0000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr.</emphasis> 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with <citetitle><emphasis>Rhizopus oryzae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3343–3344.</para>
          </listitem>
          <listitem id="ch0146s0000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR.</emphasis> 2002. In vivo activity of posaconazole against <citetitle><emphasis>Mucor</emphasis></citetitle> spp. in an immunosuppressed-mouse model. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2310–2312.</para>
          </listitem>
          <listitem id="ch0146s0000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Dannaoui E, Mouton JW, Meis JF, Verweij PE, Eurofung Network.</emphasis> 2002. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1953–1959.</para>
          </listitem>
          <listitem id="ch0146s0000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J.</emphasis> 2012. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by <citetitle><emphasis>Mucor circinelloides</emphasis></citetitle>: poor efficacy of posaconazole. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>2246–2250.</para>
          </listitem>
          <listitem id="ch0146s0000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Spellberg B, Edwards J Jr, Ibrahim A.</emphasis> 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">18:</emphasis>556–569.</para>
          </listitem>
          <listitem id="ch0146s0000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP.</emphasis> 2011. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>-<citetitle><emphasis>Rhizopus oryzae</emphasis></citetitle> pulmonary infection. <citetitle><emphasis>Virulence</emphasis></citetitle> <emphasis role="strong">2:</emphasis>348–355.</para>
          </listitem>
          <listitem id="ch0146s0000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Rodríguez MM, Pastor FJ, Sutton DA, Calvo E, Fothergill AW, Salas V, Rinaldi MG, Guarro J.</emphasis> 2010. Correlation between in vitro activity of posaconazole and in vivo efficacy against <citetitle><emphasis>Rhizopus oryzae</emphasis></citetitle> infection in mice. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1665–1669.</para>
          </listitem>
          <listitem id="ch0146s0000li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Salas V, Pastor FJ, Calvo E, Sutton DA, Chander J, Mayayo E, Alvarez E, Guarro J.</emphasis> 2012. Efficacy of posaconazole in a murine model of disseminated infection caused by <citetitle><emphasis>Apophysomyces variabilis. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1712–1715.</para>
          </listitem>
          <listitem id="ch0146s0000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Salas V, Pastor FJ, Calvo E, Sutton D, García-Hermoso D, Mayayo E, Dromer F, Fothergill A, Alvarez E, Guarro J.</emphasis> 2012. Experimental murine model of disseminated infection by <citetitle><emphasis>Saksenaea vasiformis</emphasis></citetitle>: successful treatment with posaconazole. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>710–715.</para>
          </listitem>
          <listitem id="ch0146s0000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Thompson GR III, Wiederhold NP.</emphasis> 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">170:</emphasis>291–313.</para>
          </listitem>
          <listitem id="ch0146s0000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Arendrup MC, Jensen RH, Meletiadis J.</emphasis> 2015. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>7735–7742.</para>
          </listitem>
          <listitem id="ch0146s0000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Luo G, Gebremariam T, Lee H, Edwards JE Jr, Kovanda L, Ibrahim AS.</emphasis> 2014. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>2450–2453.</para>
          </listitem>
          <listitem id="ch0146s0000li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Alastruey-Izquierdo A, Castelli MV, Cuesta I, Zaragoza O, Monzón A, Mellado E, Rodríguez-Tudela JL.</emphasis> 2009. In vitro activity of antifungals against Zygomycetes. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">15</emphasis>(Suppl 5)<emphasis role="strong">:</emphasis>71–76.</para>
          </listitem>
          <listitem id="ch0146s0000li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF.</emphasis> 2010. <citetitle><emphasis>Apophysomyces elegans</emphasis></citetitle>: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>4580–4585.</para>
          </listitem>
          <listitem id="ch0146s0000li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Peláez T, Bouza E.</emphasis> 2008. Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>225–230.</para>
          </listitem>
          <listitem id="ch0146s0000li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.</emphasis> 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1813–1821.</para>
          </listitem>
          <listitem id="ch0146s0000li0189" role="bibliographyEntry">
            <anchor id="ch0146s0000a0112"/>
            <para>189.<emphasis role="strong">Vikram HR, Smilack JD, Leighton JA, Crowell MD, De Petris G.</emphasis> 2012. Emergence of gastrointestinal basidiobolomycosis in the United States, with a review of worldwide cases. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1685–1691.</para>
          </listitem>
          <listitem id="ch0146s0000li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Cameron HM.</emphasis> 1989. Entomophthoromycosis, p 186–198. <citetitle><emphasis>In</emphasis></citetitle> Mahgoub ES (ed), <citetitle><emphasis>Tropical Mycosis.</emphasis></citetitle> Janssen Research Council, Beerse, Belgium.</para>
          </listitem>
          <listitem id="ch0146s0000li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Receveur MC, Roussin C, Mienniel B, Gasnier O, Rivière JP, Malvy D, Lortholary O.</emphasis> 2005. [Rhinofacial entomophthoromycosis. About two new cases in Mayotte]. <citetitle><emphasis>Bull Soc Pathol Exot</emphasis></citetitle> <emphasis role="strong">98:</emphasis>350–353.</para>
          </listitem>
          <listitem id="ch0146s0000li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Kimura M, Yaguchi T, Sutton DA, Fothergill AW, Thompson EH, Wickes BL.</emphasis> 2011. Disseminated human conidiobolomycosis due to <citetitle><emphasis>Conidiobolus lamprauges. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>752–756.</para>
          </listitem>
          <listitem id="ch0146s0000li0193" role="bibliographyEntry">
            <para>193.<emphasis role="strong">Gugnani HC.</emphasis> 1999. A review of zygomycosis due to <citetitle><emphasis>Basidiobolus ranarum. Eur J Epidemiol</emphasis></citetitle> <emphasis role="strong">15:</emphasis>923–929.</para>
          </listitem>
          <listitem id="ch0146s0000li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Zavasky DM, Samowitz W, Loftus T, Segal H, Carroll K.</emphasis> 1999. Gastrointestinal zygomycotic infection caused by <citetitle><emphasis>Basidiobolus ranarum</emphasis></citetitle>: case report and review. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">28:</emphasis>1244–1248.</para>
          </listitem>
          <listitem id="ch0146s0000li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Shreef K, Saleem M, Saeedd MA, Eissa M.</emphasis> 2018. Gastrointestinal basidiobolomycosis: an emerging, and a confusing, disease in children (a multicenter experience). <citetitle><emphasis>Eur J Pediatr Surg</emphasis></citetitle> <emphasis role="strong">28:</emphasis>194–199.</para>
          </listitem>
          <listitem id="ch0146s0000li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Lyon GM, Smilack JD, Komatsu KK, Pasha TM, Leighton JA, Guarner J, Colby TV, Lindsley MD, Phelan M, Warnock DW, Hajjeh RA.</emphasis> 2001. Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1448–1455.</para>
          </listitem>
          <listitem id="ch0146s0000li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Sitterlé E, Rodriguez C, Mounier R, Calderaro J, Foulet F, Develoux M, Pawlotsky JM, Botterel F.</emphasis> 2017. Contribution of ultra deep sequencing in the clinical diagnosis of a new fungal pathogen species: <citetitle><emphasis>Basidiobolus meristosporus. Front Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>334.</para>
          </listitem>
          <listitem id="ch0146s0000li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Almoosa Z, Alsuhaibani M, AlDandan S, Alshahrani D.</emphasis> 2017. Pediatric gastrointestinal basidiobolomycosis mimicking malignancy. <citetitle><emphasis>Med Mycol Case Rep</emphasis></citetitle> <emphasis role="strong">18:</emphasis>31–33.</para>
          </listitem>
          <listitem id="ch0146s0000li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Abd El Maksoud WM, Bawahab MA, Ashraf TH, Al Shehri DM, Mirza NI.</emphasis> 2018. Surgical management of colonic basidiobolomycosis among adolescent and adult patients: presentation and outcome. <citetitle><emphasis>Colorectal Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>296–303.</para>
          </listitem>
          <listitem id="ch0146s0000li0200" role="bibliographyEntry">
            <para>200.<emphasis role="strong">Bigliazzi C, Poletti V, Dell’Amore D, Saragoni L, Colby TV.</emphasis> 2004. Disseminated basidiobolomycosis in an immunocompetent woman. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1367–1369.</para>
          </listitem>
          <listitem id="ch0146s0000li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Gugnani HC.</emphasis> 1992. Entomophthoromycosis due to <citetitle><emphasis>Conidiobolus. Eur J Epidemiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>391–396.</para>
          </listitem>
          <listitem id="ch0146s0000li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Blumentrath CG, Grobusch MP, Matsiégui PB, Pahlke F, Zoleko-Manego R, Nzenze-Aféne S, Mabicka B, Sanguinetti M, Kremsner PG, Schaumburg F.</emphasis> 2015. Classification of rhinoentomophthoromycosis into atypical, early, intermediate, and late disease: a proposal. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e0003984.</para>
          </listitem>
          <listitem id="ch0146s0000li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Bittencourt AL, Marback R, Nossa LM.</emphasis> 2006. Mucocutaneous entomophthoramycosis acquired by conjunctival inoculation of the fungus. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">75:</emphasis>936–938.</para>
          </listitem>
          <listitem id="ch0146s0000li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Walker SD, Clark RV, King CT, Humphries JE, Lytle LS, Butkus DE.</emphasis> 1992. Fatal disseminated <citetitle><emphasis>Conidiobolus coronatus</emphasis></citetitle> infection in a renal transplant patient. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">98:</emphasis>559–564.</para>
          </listitem>
          <listitem id="ch0146s0000li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Sharma NL, Mahajan VK, Singh P.</emphasis> 2003. Orofacial conidiobolomycosis due to <citetitle><emphasis>Conidiobolus incongruus. Mycoses</emphasis></citetitle> <emphasis role="strong">46:</emphasis>137–140.</para>
          </listitem>
          <listitem id="ch0146s0000li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Gupta M, Narang T, Kaur RJ, Manhas A, Saikia UN, Dogra S.</emphasis> 2016. A prospective case series evaluating efficacy and safety of combination of itraconazole and potassium iodide in rhinofacial conidiobolomycosis. <citetitle><emphasis>Int J Dermatol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>208–214.</para>
          </listitem>
          <listitem id="ch0146s0000li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">Hussein MR.</emphasis> 2008. Mucocutaneous Splendore-Hoeppli phenomenon. <citetitle><emphasis>J Cutan Pathol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>979–988.</para>
          </listitem>
          <listitem id="ch0146s0000li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Gómez-Muñoz MT, Fernández-Barredo S, Martínez-Díaz RA, Pérez-Gracia MT, Ponce-Gordo F.</emphasis> 2012. Development of a specific polymerase chain reaction assay for the detection of <citetitle><emphasis>Basidiobolus. Mycologia</emphasis></citetitle> <emphasis role="strong">104:</emphasis>585–591.</para>
          </listitem>
          <listitem id="ch0146s0000li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Ben-Ze’ev I, Kenneth R.</emphasis> 1982. Features-criteria of taxonomic value in the Entomophthorales. <citetitle><emphasis>Mycotaxon</emphasis></citetitle> <emphasis role="strong">14:</emphasis>393–455.</para>
          </listitem>
          <listitem id="ch0146s0000li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Fromentin H, Ravisse P.</emphasis> 1977. [Tropical entomophthoromycoses]. <citetitle><emphasis>Acta Trop</emphasis></citetitle> <emphasis role="strong">34:</emphasis>375–394.</para>
          </listitem>
          <listitem id="ch0146s0000li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Vilela R, Silva SM, Riet-Correa F, Dominguez E, Mendoza L.</emphasis> 2010. Morphologic and phylogenetic characterization of <citetitle><emphasis>Conidiobolus lamprauges</emphasis></citetitle> recovered from infected sheep. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>427–432.</para>
          </listitem>
          <listitem id="ch0146s0000li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">Okafor JI, Testrake D, Mushinsky HR, Yangco BG.</emphasis> 1984. A <citetitle><emphasis>Basidiobolus</emphasis></citetitle> sp. and its association with reptiles and amphibians in southern Florida. <citetitle><emphasis>Sabouraudia</emphasis></citetitle> <emphasis role="strong">22:</emphasis>47–51.</para>
          </listitem>
          <listitem id="ch0146s0000li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Yangco BG, Okafor JI, TeStrake D.</emphasis> 1984. In vitro susceptibilities of human and wild-type isolates of <citetitle><emphasis>Basidiobolus</emphasis></citetitle> and <citetitle><emphasis>Conidiobolus</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">25:</emphasis>413–416.</para>
          </listitem>
          <listitem id="ch0146s0000li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Guarro J, Aguilar C, Pujol I.</emphasis> 1999. In-vitro antifungal susceptibilities of <citetitle><emphasis>Basidiobolus</emphasis></citetitle> and <citetitle><emphasis>Conidiobolus</emphasis></citetitle> spp. strains. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>557–560.</para>
          </listitem>
          <listitem id="ch0146s0000li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">Taylor GD, Sekhon AS, Tyrrell DL, Goldsand G.</emphasis> 1987. Rhinofacial zygomycosis caused by <citetitle><emphasis>Conidiobolus coronatus</emphasis></citetitle>: a case report including in vitro sensitivity to antimycotic agents. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">36:</emphasis>398–401.</para>
          </listitem>
          <listitem id="ch0146s0000li0216" role="bibliographyEntry">
            <para>216.<emphasis role="strong">Tondolo JS, de Loreto ES, Dutra V, Nakazato L, de Paula DA, Zanette RA, Alves SH, Santurio JM.</emphasis> 2013. In vitro susceptibility of <citetitle><emphasis>Conidiobolus lamprauges</emphasis></citetitle> recovered from sheep to antifungal agents. <citetitle><emphasis>Vet Microbiol</emphasis></citetitle> <emphasis role="strong">166:</emphasis>690–693.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0146s0000a0111"/>
        <beginpage pagenum="2464"/>
      </sect2>
    </sect1>
  </chapter>
